<SEC-DOCUMENT>0001104659-20-111165.txt : 20201001
<SEC-HEADER>0001104659-20-111165.hdr.sgml : 20201001
<ACCEPTANCE-DATETIME>20201001172115
ACCESSION NUMBER:		0001104659-20-111165
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20201001
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201001
DATE AS OF CHANGE:		20201001

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		201217149

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			2161401
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			2161401

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2032084d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:plx="http://protalix.com/20201001">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_plx_protalix.com_20201001 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20201001_20201001 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0001006281 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2020-10-01to2020-10-01" name="dei:EntityCentralIndexKey">0001006281</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-10-01to2020-10-01" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="plx-20201001.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2020-10-01to2020-10-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90F_edei--DocumentType_c20201001__20201001_z8Go4b2XiHDb"><ix:nonNumeric contextRef="From2020-10-01to2020-10-01" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of Earliest Event
Reported): <span id="xdx_901_edei--DocumentPeriodEndDate_c20201001__20201001_zLMvj8Aav6tg"><ix:nonNumeric contextRef="From2020-10-01to2020-10-01" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">October 1, 2020</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_908_edei--EntityRegistrantName_c20201001__20201001_zHIrNGtW0j31"><ix:nonNumeric contextRef="From2020-10-01to2020-10-01" name="dei:EntityRegistrantName">Protalix BioTherapeutics, Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified
in its charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr>
    <td style="vertical-align: top; text-align: center; width: 32%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90A_edei--EntityIncorporationStateCountryCode_c20201001__20201001_zXUZZgFPMJ96"><ix:nonNumeric contextRef="From2020-10-01to2020-10-01" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; text-align: center; width: 32%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_904_edei--EntityFileNumber_c20201001__20201001_zBGYwO5DWank"><ix:nonNumeric contextRef="From2020-10-01to2020-10-01" name="dei:EntityFileNumber">001-33357</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; text-align: center; width: 32%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_909_edei--EntityTaxIdentificationNumber_c20201001__20201001_zBOQFf6uvqZ4"><ix:nonNumeric contextRef="From2020-10-01to2020-10-01" name="dei:EntityTaxIdentificationNumber">65-0643773</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(State or other jurisdiction</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of incorporation)</b></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Commission File Number)</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(IRS Employer</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Identification No.)</b></p></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr>
    <td style="vertical-align: top; text-align: center; width: 49%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90F_edei--EntityAddressAddressLine1_c20201001__20201001_zY0W5kAvTgn2"><ix:nonNumeric contextRef="From2020-10-01to2020-10-01" name="dei:EntityAddressAddressLine1">2 Snunit Street</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; text-align: center; width: 49%"></td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_900_edei--EntityAddressAddressLine2_c20201001__20201001_ztQzcLtdXjjk"><ix:nonNumeric contextRef="From2020-10-01to2020-10-01" name="dei:EntityAddressAddressLine2">Science Park, POB 455</ix:nonNumeric></span></b></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_900_edei--EntityAddressCityOrTown_c20201001__20201001_zpmb2MgmvAOb"><ix:nonNumeric contextRef="From2020-10-01to2020-10-01" name="dei:EntityAddressCityOrTown">Carmiel</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressCountry_c20201001__20201001_zIvT3dq1wZKl"><ix:nonNumeric contextRef="From2020-10-01to2020-10-01" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">Israel</ix:nonNumeric></span></b></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_905_edei--EntityAddressPostalZipCode_c20201001__20201001_z1Giu9AcbEh9"><ix:nonNumeric contextRef="From2020-10-01to2020-10-01" name="dei:EntityAddressPostalZipCode">2161401</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Address of principal executive offices)</b></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Zip Code)</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number, including
area code +<span id="xdx_90E_edei--CityAreaCode_c20201001__20201001_zR87tPusvRM6"><ix:nonNumeric contextRef="From2020-10-01to2020-10-01" name="dei:CityAreaCode">972-4</ix:nonNumeric></span>-<span id="xdx_901_edei--LocalPhoneNumber_c20201001__20201001_zkXNvnHNMgb5"><ix:nonNumeric contextRef="From2020-10-01to2020-10-01" name="dei:LocalPhoneNumber">988-9488</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former name or former address, if changed
since last report.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see</i> General Instruction
A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_901_edei--WrittenCommunications_c20201001__20201001_zDO3lP25FSCk"><ix:nonNumeric contextRef="From2020-10-01to2020-10-01" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_909_edei--SolicitingMaterial_c20201001__20201001_zB1CJZu2jWOi"><ix:nonNumeric contextRef="From2020-10-01to2020-10-01" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_907_edei--PreCommencementTenderOffer_c20201001__20201001_zJhKLn63dnxj"><ix:nonNumeric contextRef="From2020-10-01to2020-10-01" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_900_edei--PreCommencementIssuerTenderOffer_c20201001__20201001_zXE49Y8qa1ad"><ix:nonNumeric contextRef="From2020-10-01to2020-10-01" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities registered pursuant to Section
12(b) of the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border: black 1pt solid; width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Title of each class</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Trading Symbol(s)</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Name of each exchange on which registered</span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_edei--Security12bTitle_c20201001__20201001_zgCMQ0faLhy7"><ix:nonNumeric contextRef="From2020-10-01to2020-10-01" name="dei:Security12bTitle">Common stock, $0.001 par value</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_edei--TradingSymbol_c20201001__20201001_zQdHSDLWHoo"><ix:nonNumeric contextRef="From2020-10-01to2020-10-01" name="dei:TradingSymbol">PLX</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_edei--SecurityExchangeName_c20201001__20201001_zHjw2dMRSPRg"><ix:nonNumeric contextRef="From2020-10-01to2020-10-01" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NYSE American</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3in 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3in 0pt 0">Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR &#167;240.12b-2).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3in 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in; text-align: center; text-indent: 0.5in">Emerging growth
company <span style="font-family: Wingdings"><span id="xdx_900_edei--EntityEmergingGrowthCompany_c20201001__20201001_z9PtAYcEuTm5"><ix:nonNumeric contextRef="From2020-10-01to2020-10-01" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in; text-align: center; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 12%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
1.01</b></span></td>
    <td style="width: 88%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Entry into a Material Definitive Agreement.</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">On
October 1, 2020, Protalix BioTherapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;), entered into an ATM Equity
Offering<sup>SM</sup> Sales Agreement (the &#8220;Sales Agreement&#8221;) with BofA Securities, Inc., as the Company&#8217;s sales
agent (the &#8220;Agent&#8221;). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the
Agent shares of the Company&#8217;s common stock having an aggregate offering price of up to $30 million (the &#8220;Shares&#8221;).
The Shares will be issued pursuant to the Company&#8217;s shelf registration statement on Form S-3 (Registration No. 333-230604).</span>
The Company intends to use the net proceeds from the offering, after deducting the Agent&#8217;s commissions and the Company&#8217;s
offering expenses, for general corporate purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">In
accordance with the terms of the Sales Agreement, the Company may offer and sell the Shares at any time and from time to time through
the Agent. Sales of the Shares, if any, will be made by means of transactions that are deemed to be &#8220;at the market&#8221;
offerings as defined in Rule 415 under the Securities Act of 1933, as amended, including block trades and sales made in ordinary
brokers&#8217; transactions on the NYSE American or otherwise at market prices prevailing at the time of the sale, at prices related
to prevailing market prices or at negotiated prices. Under the terms of the Sales Agreement, the Company may also sell Shares to
</span>the Agent as principal for its own account at a price to be agreed upon at the time of sale. Any sale of Shares to the Agent
as principal would be pursuant to the terms of a separate terms agreement between the Company and the Agent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">The
foregoing description of the Sales Agreement in this report does not purport to be complete and is qualified by reference to the
full text of the Sales Agreement, which is filed as Exhibit 1.1 hereto. The legal opinion and consent relating to the Shares are
included as Exhibits 5.1 and 23.1,</span> respectively, hereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Current Report on Form 8-K shall not constitute an offer
to sell or the solicitation of an offer to buy any Shares, nor shall there be any sale of Shares in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of
any such state or other jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <td style="width: 12%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
9.01</b></span></td>
    <td style="width: 88%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Financial Statements and Exhibits</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) Exhibits:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">Exhibit No.</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Description</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 8%; text-align: left"><a href="tm2032084d1_ex1-1.htm" style="-sec-extract: exhibit">1.1</a></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: left"><a href="tm2032084d1_ex1-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">ATM Equity Offering<sup>SM</sup> Sales Agreement, dated October 1, 2020, between the Company and BofA Securities, Inc.</span></a></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><a href="tm2032084d1_ex5-1.htm" style="-sec-extract: exhibit">5.1</a></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="tm2032084d1_ex5-1.htm" style="-sec-extract: exhibit">Opinion of Mayer Brown LLP</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><a href="tm2032084d1_ex5-1.htm" style="-sec-extract: exhibit">23.1</a></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="tm2032084d1_ex5-1.htm" style="-sec-extract: exhibit">Consent of Mayer Brown LLP (included in Exhibit 5.1)</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">104</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
<tr>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Date: October&#160;1,
    2020</span></td>
    <td colspan="3" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>PROTALIX
    BIOTHERAPEUTICS, INC.</b></span></td></tr>
<tr>
    <td style="text-align: justify">&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td></tr>
<tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">/s/
    Dror Bashan</span></td></tr>
<tr>
    <td style="text-align: justify; width: 50%">&#160;</td>
    <td style="text-align: justify; width: 5%">&#160;</td>
    <td style="width: 5%">Name:</td>
    <td style="width: 40%">Dror Bashan</td></tr>
<tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>Title:</td>
    <td>President and Chief Executive Officer</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify; text-indent: -3.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify; text-indent: -3.5in"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify; text-indent: -3.5in">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdsKgkAQhp/Adxj2Omq1w4WXSUVkISLR7aJjLOmOzG4HH6m3bFOiYWBO/ze/EBOxo61ukOGyzlMosO0a5RByrJHRlOgVyf4Qg685XrV1rIwbxh+YkGfQM8vpvPT7QfnQFqsY5Gom57NI+iZehJAdRfC9J2RqXaFxWjWgTAUZU8caneJ+/FCoFxlq+8HpjGw1mRjCqRzPb4hkGMGJHupJfLOQpokIJkMEYsd07742d+uohU2DrfeyI/rP4APcfUkX -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm2032084d1_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 1.1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">EXECUTION VERSION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Protalix BioTherapeutics, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Common Stock<BR>
($0.001 par value)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ATM EQUITY OFFERING<SUP>SM</SUP> SALES
AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">October 1, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">BofA Securities, Inc. </FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">One Bryant Park</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">New York, New York 10036</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As Agent</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Protalix BioTherapeutics, Inc., a Delaware
corporation (the &ldquo;<U>Company</U>&rdquo;), proposes, subject to the terms and conditions stated herein, to issue and sell
from time to time to or through BofA Securities, Inc., as sales agent and/or principal (the &ldquo;<U>Agent</U>&rdquo;), shares
(the &ldquo;<U>Shares</U>&rdquo;) of the Company&rsquo;s common stock, $0.001 par value (the &ldquo;<U>Common Stock</U>&rdquo;),
having an aggregate gross sales price not to exceed $30,000,000, on the terms set forth in this ATM Equity Offering<SUP>SM</SUP>
Sales Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company agrees that whenever it determines
to sell Shares directly to the Agent as principal it will enter into a separate written Terms Agreement (each, a &ldquo;<U>Terms
Agreement</U>&rdquo;), in substantially the form of Annex I hereto, relating to such sale in accordance with Section 2(k) hereof.
References herein to &ldquo;this Agreement&rdquo; or to matters contained &ldquo;herein&rdquo; or &ldquo;hereunder,&rdquo; or words
of similar import, mean this ATM Equity Offering<SUP>SM</SUP> Sales Agreement and any applicable Terms Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company has prepared and filed with
the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) a shelf registration statement on Form S-3 (File No.
333-230604) covering the public offering and sale of certain securities of the Company, including the Shares, under the Securities
Act of 1933, as amended (the &ldquo;<U>1933 Act</U>&rdquo;) and the rules and regulations promulgated thereunder (the &ldquo;<U>1933
Act Regulations</U>&rdquo;), which shelf registration statement was declared effective by the Commission on April 12, 2019. The
 &ldquo;<U>Registration Statement</U>,&rdquo; as of any time, means such registration statement as amended by any post-effective
amendments thereto at such time, including the exhibits and any schedules thereto at such time, the documents incorporated or deemed
to be incorporated by reference therein at such time pursuant to Item 12 of Form S-3 under the 1933 Act and the documents otherwise
deemed to be a part thereof as of such time pursuant to Rule 430B of the 1933 Act Regulations (&ldquo;<U>Rule 430B</U>&rdquo;);
<U>provided</U>, <U>however</U>, that the &ldquo;Registration Statement&rdquo; without reference to a time means such registration
statement as amended by any post-effective amendments thereto as of the time of the first contract of sale for the Shares, which
time shall be considered the &ldquo;new effective date&rdquo; of the Registration Statement with respect to the Shares within the
meaning of paragraph (f)(2) of Rule 430B (&ldquo;<U>Rule 430B(f)(2</U>)&rdquo;), including the exhibits and schedules thereto at
such time, the documents incorporated or deemed to be incorporated by reference therein at such time pursuant to Item 12 of Form
S-3 under the 1933 Act and the documents otherwise deemed to be a part thereof as of such time pursuant to Rule 430B. The base
prospectus filed as part of such shelf registration statement, as amended in the form in which it has been filed most recently
with the Commission in accordance with Section 3(b) or 3(c) hereof, including the documents incorporated or deemed to be incorporated
by reference therein pursuant to Item 12 of Form S-3 under the 1933 Act, is referred to herein as the &ldquo;<U>Base Prospectus</U>.&rdquo;
Promptly after execution and delivery of this Agreement, the Company will prepare and file a prospectus supplement relating to
the Shares in accordance with the provisions of Rule 424(b) of the 1933 Act Regulations (&ldquo;<U>Rule 424(b)</U>&rdquo;). Such
final prospectus supplement, as amended by the prospectus supplement filed most recently with the Commission in accordance with
Section 3(b), 3(c) or 3(n) hereof, as the case may be, including the documents incorporated or deemed to be incorporated by reference
therein pursuant to Item 12 of Form S-3 under the 1933 Act, is referred to herein as the &ldquo;<U>Prospectus Supplement</U>.&rdquo;
The Base Prospectus, as amended by the Prospectus Supplement and any applicable pricing supplement thereto, in the forms of the
Base Prospectus, the Prospectus Supplement and any such pricing supplement are first furnished to the Agent for use in connection
with the offering and sale of Shares, are collectively referred to herein as the &ldquo;<U>Prospectus</U>.&rdquo; For purposes
of this Agreement, all references to the Registration Statement, any preliminary prospectus or the Prospectus or any amendment
or supplement thereto shall be deemed to include the copy filed with the Commission pursuant to its Electronic Data Gathering,
Analysis and Retrieval system (or any successor system) (&ldquo;<U>EDGAR</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As used in this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Applicable Time</U>&rdquo;
means, with respect to any offer and sale of Shares, the time immediately prior to the first contract of sale for such Shares,
or such other time as agreed by the Company and the Agent).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>General Disclosure Package</U>&rdquo;
means each Issuer General Use Free Writing Prospectus, if any, issued prior to the Applicable Time, the most recent Prospectus
filed with the Commission in accordance with Section 3(b), 3(c) or 3(n) hereof that is distributed to investors prior to the Applicable
Time and the number of Shares and the initial offering price per Share, all considered together.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Issuer Free Writing
Prospectus</U>&rdquo; means any &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433 of the 1933 Act Regulations
(&ldquo;<U>Rule 433</U>&rdquo;), including, without limitation, any &ldquo;free writing prospectus&rdquo; (as defined in Rule 405)
relating to the Shares that is (i) required to be filed with the Commission by the Company, (ii) a &ldquo;road show that is a written
communication&rdquo; within the meaning of Rule 433(d)(8)(i), whether or not required to be filed with the Commission, or (iii)
exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) because it contains a description of the Shares or of the
offering thereof that does not reflect the final terms, in each case in the form filed or required to be filed with the Commission
or, if not required to be filed, in the form retained in the Company&rsquo;s records pursuant to Rule 433(g).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Issuer General Use Free
Writing Prospectus</U>&rdquo; means any Issuer Free Writing Prospectus approved by the Agent or, in the case of a specific offer
and sale of Shares, the Agent pursuant to Section 3(l) hereof that is furnished to the Agent, as the case may be, for general distribution
to investors, as evidenced by communications between the Company and the Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Issuer Limited Use Free
Writing Prospectus</U>&rdquo; means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All references in this Agreement to financial
statements and schedules and other information which is &ldquo;contained,&rdquo; &ldquo;included,&rdquo; &ldquo;made,&rdquo; &ldquo;stated&rdquo;
or &ldquo;referred to&rdquo; (or other references of like import) in the Registration Statement, any preliminary prospectus or
the Prospectus shall be deemed to include all such financial statements and schedules and other information incorporated or deemed
to be incorporated by reference in the Registration Statement, any preliminary prospectus or the Prospectus, as the case may be,
prior to the Applicable Time relating to the particular Shares&#894; and all references in this Agreement to amendments or supplements
to the Registration Statement, any preliminary prospectus or the Prospectus shall be deemed to include the filing of any document
under the Securities Exchange Act of 1934, as amended (the &ldquo;<U>1934 Act</U>&rdquo;), and the rules and regulations promulgated
thereunder (the &ldquo;<U>1934 Act Regulations</U>&rdquo;) incorporated or deemed to be incorporated by reference in the Registration
Statement, such preliminary prospectus or the Prospectus, as the case may be, at or after the Applicable Time relating to the particular
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Representations
and Warranties<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></U><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;(a)
The Company represents and warrants to the Agent at the date of this Agreement, each Registration Statement Amendment Date (as
defined in Section 3(o) hereof), each Company Periodic Report Date (as defined in Section 3(n) hereof), each Company Earnings
Report Date (as defined in Section 3(o) hereof), each Request Date (as defined in Section 3(o) hereof), each Applicable Time and
each Settlement Date (as defined in Section 2(h) hereof) (collectively, a &ldquo;Representation Date&rdquo;), and agrees with
the Agent, as follows:</FONT></P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="color: #010000">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Compliance of the Registration Statement, the Prospectus and Incorporated Documents</U>. The Company meets the
requirements for use of Form S-3 under the 1933 Act. The Registration Statement is a shelf registration statement and the Shares
have been and remain eligible for registration by the Company on such shelf registration statement. Each of the Registration Statement
and any post-effective amendment thereto has become effective under the 1933 Act. No stop order suspending the effectiveness of
the Registration Statement or any post-effective amendment thereto has been issued under the 1933 Act, no notice of objection of
the Commission to the use of the Registration Statement or any post-effective amendment thereto pursuant to Rule 401(g)(1) of the
1933 Act Regulations (&ldquo;<U>Rule 401(g)(1)</U>&rdquo;) has been received by the Company, no order preventing or suspending
the use of any preliminary prospectus or the Prospectus or any amendment or supplement thereto has been issued and no proceedings
for any of those purposes have been instituted or are pending or, to the Company&rsquo;s knowledge, contemplated. The Company has
complied with each request (if any) from the Commission for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 31.5pt">Each of the Registration Statement
and any post-effective amendment thereto, at the time of its effectiveness and as of each deemed effective date with respect to
the Agent pursuant to Rule 430B(f)(2), complied in all material respects with the requirements of the 1933 Act and the 1933 Act
Regulations. Each of any preliminary prospectus and the Prospectus and any amendment or supplement thereto, at the time it was
filed with the Commission, complied in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations
and is identical to the electronically transmitted copy thereof filed with the Commission pursuant to EDGAR, except to the extent
permitted by Regulation S-T.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 31.5pt">The documents incorporated or
deemed to be incorporated by reference in the Registration Statement, any preliminary prospectus and the Prospectus, when they
became effective or at the time they were or hereafter are filed with the Commission, complied and will comply in all material
respects with the requirements of the 1934 Act and the 1934 Act Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Accurate
Disclosure</U>. Neither the Registration Statement nor any amendment thereto, at its effective time or at any Settlement Date,
contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material
fact required to be stated therein or necessary to make the statements therein not misleading. At each Applicable Time, neither
(A) the General Disclosure Package nor (B) any individual Issuer Limited Use Free Writing Prospectus, when considered together
with the General Disclosure Package, included, includes or will include an untrue statement of a material fact or omitted, omits
or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading. Neither the Prospectus nor any amendment or supplement thereto (including any prospectus
wrapper), as of its issue date, at the time of any filing with the Commission pursuant to Rule 424(b) or at any Settlement Date,
included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact
necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.
The documents incorporated or deemed to be incorporated by reference in the Registration Statement, the General Disclosure Package
and the Prospectus, at the time the Registration Statement became effective or when such documents incorporated by reference were
or hereafter are filed with the Commission, as the case may be, when read together with the other information in the Registration
Statement, the General Disclosure Package or the Prospectus, as the case may be, did not, do not and will not include an untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Issuer
Free Writing Prospectuses</U>. No Issuer Free Writing Prospectus conflicts or will conflict with the information contained in
the Registration Statement, any preliminary prospectus or the Prospectus or any amendment or supplement thereto, including any
document incorporated by reference therein, that has not been superseded or modified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>[Reserved].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Company Not Ineligible Issuer</U>. (A) At the time of filing the Registration Statement and any post-effective
amendment thereto, (B) at the earliest time thereafter that the Company or another offering participant made a <I>bona fide </I>offer
(within the meaning of Rule 164(h)(2) of the 1933 Act Regulations) of the Shares, (C) at the date of this Agreement and any Terms
Agreement and (D) at each Applicable Time, the Company was not and is not an &ldquo;ineligible issuer,&rdquo; as defined in Rule
405, without taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company
be considered an ineligible issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Independent Accountants</U>. Kesselman &amp; Kesselman, a member of PricewaterhouseCoopers International Limited,
who has certified the financial statements and supporting schedules included in the Registration Statement, the General Disclosure
Package and the Prospectus is an independent public accountant as required by the 1933 Act, the 1933 Act Regulations, the 1934
Act, the 1934 Act Regulations and the Public Company Accounting Oversight Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Financial Statements&#894; Non-GAAP Financial Measures</U>. The financial statements of the Company included in
the Registration Statement, the General Disclosure Package and the Prospectus, together with the related schedules and notes, present
fairly in all material respects the financial position of the Company and its consolidated subsidiaries at the dates indicated
and the statement of operations, stockholders&rsquo; equity and cash flows of the Company and its consolidated subsidiaries for
the periods specified; said financial statements have been prepared in conformity with U.S. generally accepted accounting principles
(&ldquo;<U>GAAP</U>&rdquo;) applied on a consistent basis throughout the periods involved. The financial statements of the businesses
acquired or proposed to be acquired, if any, included in the Registration Statement, the General Disclosure Package and the Prospectus
present fairly in all material respects the information set forth therein, have been prepared in conformity with GAAP applied on
a consistent basis and otherwise have been prepared in accordance with, in the case of businesses acquired or to be acquired, the
applicable financial statement requirements of Rule 3-05. Any pro forma financial statements and the related notes thereto included
in the Registration Statement, the General Disclosure Package and the Prospectus present fairly in all material respects the information
shown therein, have been prepared in accordance with the Commission&rsquo;s rules and guidelines with respect to pro forma financial
statements and have been properly compiled on the bases described therein, and the assumptions used in the preparation thereof
are reasonable and the adjustments used therein are appropriate to give effect to the transactions and circumstances referred to
therein. Except as included in the Registration Statement, the General Disclosure Package and the Prospectus, no historical or
pro forma financial statements or supporting schedules are required to be included in the Registration Statement, any preliminary
prospectus or the Prospectus under the 1933 Act or the 1933 Act Regulations. The interactive data in eXtensible Business Reporting
Language incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus fairly presents
in all material respects the required information and has been prepared in accordance with the Commission's rules and guidelines
applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>No Material Adverse Change</U>. Except as stated in the Registration Statement, the General Disclosure Package
and the Prospectus, since the respective dates as of which information is given in the Registration Statement, the General Disclosure
Package or the Prospectus, (A) there has been no material adverse change in the condition, financial or otherwise, or in the earnings,
business affairs or business prospects of the Company and its subsidiaries considered as one enterprise, whether or not arising
in the ordinary course of business (a &ldquo;<U>Material Adverse Change</U>&rdquo;), (B) there have been no transactions entered
into by the Company or any of its subsidiaries, other than those in the ordinary course of business, which are material with respect
to the Company and its subsidiaries considered as one enterprise, and (C) there has been no dividend or distribution of any kind
declared, paid or made by the Company on any class or series of its capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Good Standing of the Company</U>. The Company has been duly incorporated and is validly existing as a corporation
in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to own, lease and
operate its properties and to conduct its business as described in the Registration Statement, the General Disclosure Package and
the Prospectus and to enter into and perform its obligations under, and to consummate the transactions contemplated in, this Agreement.
The Company is duly qualified as a foreign corporation to transact business and is in good standing in each jurisdiction in which
such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where
the failure so to qualify or to be in good standing would not, singly or in the aggregate, reasonably be expected to result in
a material adverse effect in (A) the condition, financial or otherwise, or in the earnings, business affairs or business prospects
of the Company and its subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business, or
(B) the ability of the Company to enter into and perform any of its obligations under, or to consummate any of the transactions
contemplated in, this Agreement (collectively, a &ldquo;<U>Material Adverse Effect</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Good
Standing of Subsidiaries</U>. Each &ldquo;significant subsidiary&rdquo; of the Company (as such term is defined in Rule 1-02 of
Regulation S-X), if any (each, a &ldquo;<U>Significant Subsidiary</U>&rdquo; and, collectively, the &ldquo;<U>Significant Subsidiaries</U>&rdquo;)
has been duly organized and is validly existing in good standing under the laws of the jurisdiction of its incorporation or organization,
has all requisite power and authority to own, lease and operate its properties and to conduct its business as described in the
Registration Statement, the General Disclosure Package and the Prospectus and is duly qualified to transact business and is in
good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property
or the conduct of business, except where the failure so to qualify or to be in good standing would not, singly or in the aggregate,
reasonably be expected to result in a Material Adverse Effect. Except as described in the Registration Statement, the General
Disclosure Package and the Prospectus, all of the outstanding shares of capital stock or other equity interests in each Significant
Subsidiary have been duly authorized and validly issued, are fully paid and non-assessable and are owned by the Company, directly
or through other subsidiaries of the Company, free and clear of any security interest, mortgage, pledge, lien, encumbrance, claim
or equity. None of the outstanding shares of capital stock of or other equity interests in any Significant Subsidiary were issued
in violation of the preemptive or similar rights of any securityholder of such Significant Subsidiary or any other person or entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Capitalization&#894;
Listing of Common Stock</U>. The authorized, issued and outstanding shares of capital stock of the Company are as set forth in
the Registration Statement and the Prospectus (except for subsequent issuances, if any, pursuant to this Agreement, pursuant to
reservations, agreements or employee benefit plans referred to in the Registration Statement, the General Disclosure Package and
the Prospectus or pursuant to the exercise of convertible securities or options referred to in the Registration Statement, the
General Disclosure Package and the Prospectus). The outstanding shares of capital stock of the Company have been duly authorized
and validly issued and are fully paid and non-assessable. None of the outstanding shares of capital stock of the Company were
issued in violation of the preemptive or other similar rights of any securityholder of the Company or any other person or entity.
The Company&rsquo;s Common Stock has been registered pursuant to Section 12(b) of the 1934 Act and the Shares have been approved
for listing, subject to official notice of issuance, on the NYSE American LLC (the &ldquo;<U>NYSE American</U>&rdquo;), and the
Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Stock under
the 1934 Act or the listing of the Common Stock on the NYSE American, nor has the Company received any notification that the Commission
or the NYSE American is contemplating terminating such registration or listing, except as stated in the Registration Statement,
the General Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Authorization of this Agreement</U>. This Agreement has been duly authorized, executed and delivered by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xiii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Authorization and Description of Shares</U>. The Shares have been duly authorized for issuance and sale by the
Company pursuant to this Agreement and, when issued and delivered by the Company pursuant to this Agreement against payment of
the consideration set forth in this Agreement, will be validly issued, fully paid and non-assessable. The issuance of the Shares
is not subject to the preemptive or other similar rights of any securityholder of the Company or any other person or entity. The
Common Stock conforms to all statements relating thereto contained in the Registration Statement, the General Disclosure Package
and the Prospectus and such statements conform to the rights set forth in the instruments defining the same. No holder of Shares
will be subject to personal liability by reason of being such a holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xiv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Registration Rights</U>. There are no persons with registration rights or other similar rights to have any securities
registered for sale pursuant to the Registration Statement or otherwise registered for sale or sold by the Company under the 1933
Act pursuant to this Agreement, other than those rights that have been disclosed in the Registration Statement, the General Disclosure
Package and the Prospectus and have been waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Absence of Violations, Defaults and Conflicts</U>. Neither the Company nor any of its subsidiaries are (A) in
violation of its charter, by-laws or similar organizational document, (B) in default in the performance or observance of any obligation,
agreement, covenant or condition contained in any contract, indenture, mortgage, deed of trust, loan or credit agreement, note,
lease or other agreement or instrument to which the Company or any of its subsidiaries are a party or by which it or any of them
may be bound or to which any of the properties, assets or operations of the Company or any of its subsidiaries are subject (collectively,
 &ldquo;<U>Agreements and Instruments</U>&rdquo;), except for such defaults that would not, singly or in the aggregate, reasonably
be expected to result in a Material Adverse Effect, or (C) in violation of any law, statute, rule, regulation, judgment, order,
writ or decree of any arbitrator, court, governmental body, regulatory body, administrative agency or other authority, body or
agency having jurisdiction over the Company or any of its subsidiaries or any of their respective properties, assets or operations
(each, a &ldquo;<U>Governmental Entity</U>&rdquo;), except for such violations that would not, singly or in the aggregate, reasonably
be expected to result in a Material Adverse Effect. The execution, delivery and performance of this Agreement and the consummation
of the transactions contemplated herein and in the Registration Statement, the General Disclosure Package and the Prospectus (including
the issuance and sale of Shares and the use of the proceeds from the sale thereof as described therein under the caption &ldquo;Use
of Proceeds&rdquo;) and compliance by the Company with its obligations hereunder have been duly authorized by all requisite action
and do not and will not, whether with or without the giving of notice or passage of time or both, conflict with or constitute a
breach of, or default or Repayment Event (as defined below) under, or result in the creation or imposition of any lien, charge
or encumbrance upon any properties, assets or operations of the Company or any of its subsidiaries pursuant to, the Agreements
and Instruments (except for such conflicts, breaches, defaults or Repayment Events or liens, charges or encumbrances that would
not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect), nor will such action result in
any violation of the provisions of (a) the charter, by-laws or similar organizational document of the Company or any of its subsidiaries
or (b) any law, statute, rule, regulation, judgment, order, writ or decree of any Governmental Entity, except in the case of clause
(b), as would not singly or in the aggregate, reasonably be expected to have a Material Adverse Effect. As used herein, a &ldquo;<U>Repayment
Event</U>&rdquo; means any event or condition which gives the holder of any note, debenture or other financing instrument (or any
person acting on such holder&rsquo;s behalf) the right to require the repurchase, redemption or repayment of all or a portion of
the related financing by the Company or any of its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xvi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Absence
of Labor Dispute</U>. No labor dispute with the employees of the Company or any of its subsidiaries exists or, to the knowledge
of the Company, is imminent, which could, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xvii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Absence
of Proceedings</U>. Except as stated in the Registration Statement, the General Disclosure Package and the Prospectus, there is
no action, suit, proceeding, inquiry or investigation before or brought by any Governmental Entity now pending or, to the knowledge
of the Company, threatened, against or affecting the Company or any of its subsidiaries, which could, singly or in the aggregate,
reasonably be expected to result in a Material Adverse Effect. The aggregate of all pending legal or governmental proceedings
to which the Company or any of its subsidiaries are a party or of which any of their respective properties, assets or operations
are the subject which are not described in the Registration Statement, the General Disclosure Package and the Prospectus, including
ordinary routine litigation incidental to the business, would not, singly or in the aggregate, reasonably be expected to result
in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xviii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Accuracy
of Exhibits</U>. There are no contracts or documents which are required to be described in all material respects in the Registration
Statement, any preliminary prospectus or the Prospectus or to be filed as exhibits to the Registration Statement which have not
been so described and filed as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Absence
of Further Requirements</U>. No filing with, or authorization, approval, consent, license, order, registration, qualification
or decree of, any Governmental Entity is necessary or required for the Company&rsquo;s due authorization, execution and delivery
of, or performance of its obligations under, this Agreement or for the offering, issuance, sale or delivery of Shares or the consummation
of the transactions contemplated in this Agreement except such as have been already obtained or as may be required under the 1933
Act, the 1933 Act Regulations, the rules of the NYSE American, the securities laws of any state or non-U.S. jurisdiction or the
rules of Financial Industry Regulatory Authority, Inc. (&ldquo;<U>FINRA</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xx)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Possession
of Licenses and Permits</U>. The Company and its subsidiaries possess and are in compliance in all material respects with the
terms of all licenses, approvals, orders, certificates, permits and other authorizations (collectively, &ldquo;<U>Licenses</U>&rdquo;)
issued by all applicable authorities, including, without limitation, all such Licenses required by the U.S. Food and Drug Administration
or any component thereof and/or by any other U.S. state, local or foreign government or drug regulatory agency (collectively,
the &ldquo;<U>Regulatory Agencies</U>&rdquo;) necessary to conduct their respective businesses as described in the Registration
Statement, the General Disclosure Package and the Prospectus, as applicable, and neither the Company nor any such subsidiary has
received any notice of proceedings (or otherwise) relating to the revocation or modification of, or non-compliance with, any such
License that, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected
to have a Material Adverse Effect, except as set forth or contemplated in the Registration Statement, the General Disclosure Package
and the Prospectus, and all such Licenses are in full force and effect. The Company and its subsidiaries are in compliance with
all statutes, rules and regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use,
distribution, storage, import, export or disposal of any product manufactured or distributed by them, except where such noncompliance
would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xxi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Title to Property</U>. The Company and its subsidiaries have good and marketable title to all real property owned
by them and good title to all other properties owned by them that is material to the business of the Company and its subsidiaries,
in each case, free and clear of all mortgages, pledges, liens, security interests, claims, restrictions or encumbrances of any
kind except such as (A) are described in the Registration Statement, the General Disclosure Package and the Prospectus or (B) do
not, singly or in the aggregate, materially affect the value of such property and do not materially interfere with the use made
and proposed to be made of such property by the Company or any of its subsidiaries. All of the leases and subleases material to
the business of the Company and its subsidiaries, considered as one enterprise, and under which the Company or any of its subsidiaries
holds properties described in the Registration Statement, the General Disclosure Package or the Prospectus, are in full force and
effect, and neither the Company nor any such subsidiary has any notice of any material claim of any sort that has been asserted
by anyone adverse to its rights under any of the leases or subleases mentioned above or affecting or questioning its rights to
the continued possession of the leased or subleased premises under any such lease or sublease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xxii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Possession of Intellectual Property</U>. The Company and its subsidiaries own, possess, have a valid license or
otherwise have adequate rights to use, on reasonable terms, all patents, trademarks, service marks, trade names, Internet domain
names, copyrights and copyrightable works, licenses, inventions, trade secrets, technology, and software, data, know-how (whether
or not patentable) and other intellectual property or proprietary rights (including all registrations and applications for registration
and renewals of, and all goodwill associated with, the foregoing) (collectively, the &ldquo;<U>Intellectual Property</U>&rdquo;)
necessary for the conduct of the Company&rsquo;s and its subsidiaries&rsquo; businesses as now conducted and intended to be conducted.
Except as would not reasonably be expected to have, singly or in the aggregate, a Material Adverse Effect: (a) there are no rights
of third parties to any such Intellectual Property; (b) to the Company&rsquo;s knowledge, there is no material infringement, misappropriation
or other violation by third parties of any such Intellectual Property; (c) there is no pending or, to the Company&rsquo;s knowledge,
threatened action, suit, proceeding or claim by others challenging the Company&rsquo;s or its subsidiaries&rsquo; rights in or
to any such Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such claim;
(d) such Intellectual Property is subsisting and, to the knowledge of the Company, valid and enforceable, and there is no pending
or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others challenging the validity, enforceability
or scope of any such Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any
such claim; (e) to the knowledge of the Company, the Company and its subsidiaries do not engage in any activity that, and there
is no pending or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others that the Company or
any of its subsidiaries, infringes, misappropriates or otherwise violates any Intellectual Property or other proprietary rights
of others, and the Company is unaware of any other fact which would form a reasonable basis for any such claim; (f) to the Company&rsquo;s
knowledge there is no U.S. patent or published U.S. patent application which contains claims that have (or may have) priority over
or dominate (or may dominate) any Intellectual Property described in the Registration Statement, the General Disclosure Package
and the Prospectus as being owned by or licensed to the Company or its subsidiaries or that interferes with the issued or pending
claims of any such Intellectual Property; and (g) there is no prior art of which the Company is aware that may render any U.S.
patent held by the Company or its subsidiaries invalid or any U.S. patent application held by the Company or its subsidiaries unpatentable
that has not been disclosed to the U.S. Patent and Trademark Office. Each current and former employee and officer of the Company
and its subsidiaries or any Affiliate has executed a valid written agreement with the Company or such subsidiary or Affiliate regarding
confidentiality and the assignment of all proprietary information and inventions created by such person. Each current and former
consultant to the Company and its subsidiaries or any Affiliate that may be involved in the generation of Intellectual Property
has executed a valid written agreement with the Company or such subsidiary or Affiliate regarding confidentiality and the assignment
of all proprietary information and inventions created by such person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xxiii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Environmental Laws</U>. Except as described in the Registration Statement, the General Disclosure Package and
the Prospectus or would not, singly or in the aggregate, result in a Material Adverse Effect, neither the Company nor any of its
subsidiaries (a) are in violation of any and all applicable foreign, federal, state and local laws and regulations (including common
law and any binding judicial or administrative decisions) relating to the protection of human health and safety, the environment
(including sustainability and the protection of habitats or ecosystems) or hazardous, toxic or radioactive substances or wastes,
pollutants or contaminants (including greenhouse gases) (&ldquo;<U>Environmental Laws</U>&rdquo;); (b) have received and are in
compliance with all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their
respective businesses; and (c) have not received any notice, demand or claim alleging any actual or potential noncompliance with
or liability under any Environmental Law or permit, license or approval thereunder and are not aware of any fact or circumstance
that would reasonably be expected to form the basis of any such notice, demand or claim. Except as set forth in the Registration
Statement, the General Disclosure Package and the Prospectus, neither the Company nor any of its subsidiaries has been named as
a &ldquo;potentially responsible party&rdquo; under the Comprehensive Environmental Response, Compensation and Liability Act of
1980, as amended. In the ordinary course of its business, the Company periodically reviews the effect of Environmental Laws on
the business, operations and properties of the Company and its subsidiaries, in the course of which it identifies and evaluates
associated costs and liabilities (including, without limitation, any capital or operating expenditures required for clean-up, closure
of properties or compliance with Environmental Laws or any permit, license, registration or approval, any related constraints on
operating activities and any potential liabilities to third parties); on the basis of such review, the Company has reasonably concluded
that such associated costs and liabilities would not, singly or in the aggregate, reasonably be expected to have a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xxiv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Accounting
Controls and Disclosure Controls</U>. The Company maintains effective internal control over financial reporting (as defined under
Rule 13-a15 and Rule 15d-15 of the 1934 Act Regulations) and a system of internal accounting controls sufficient to provide reasonable
assurances that: (A) transactions are executed in accordance with management&rsquo;s general or specific authorization; (B) transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability
for assets; (C) access to assets is permitted only in accordance with management&rsquo;s general or specific authorization; (D)
the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is
taken with respect to any differences; and (E) the interactive data in eXtensible Business Reporting Language incorporated by
reference in the Registration Statement, the General Disclosure Package and the Prospectus fairly presents in all material respects
the required information and is prepared in accordance with the Commission&rsquo;s rules and guidelines applicable thereto. Except
as described in the Registration Statement, the General Disclosure Package and the Prospectus, since the end of the Company&rsquo;s
most recent audited fiscal year, there has been (1) no material weakness in the Company&rsquo;s internal control over financial
reporting (whether or not remediated) and (2) no change in the Company&rsquo;s internal control over financial reporting that
has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial reporting.
The Company maintains an effective system of disclosure controls and procedures (as defined in Rule 13a-15 and Rule 15d-15 of
the 1934 Act Regulations) that are designed to ensure that the information required to be disclosed by the Company in the reports
that it files or submits under the 1934 Act is recorded, processed, summarized and reported within the time periods specified
in the Commission&rsquo;s rules and forms, and is accumulated and communicated to the Company&rsquo;s management, including its
principal executive officer or officers and principal financial officer or officers, as appropriate, to allow timely decisions
regarding disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xxv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Compliance
with the Sarbanes-Oxley Act</U>. There is and has been no failure on the part of the Company or any of the Company&rsquo;s directors
or officers, in their capacities as such, to comply in all material respects with any provision of the Sarbanes-Oxley Act of 2002,
as amended, and the rules and regulations promulgated in connection therewith, including, without limitation, Section 402 related
to loans and Sections 302 and 906 related to certifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xxvi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Payment
of Taxes</U>. All United States federal, state, local and non-U.S. tax returns of the Company and its subsidiaries required by
law to be filed have been filed, except where the failure to do so would not, singly or in the aggregate, reasonably be expected
to have a Material Adverse Effect and all taxes shown by such returns or otherwise assessed, which are due and payable, have been
paid, except assessments against which appeals have been or will be promptly taken and as to which adequate reserves have been
provided in accordance with GAAP by the Company. Except as otherwise disclosed in or contemplated by the Registration Statement
or the Prospectus, no tax deficiency has been determined adversely to the Company which has had, or would reasonably be expected
to have, individually or in the aggregate, a Material Adverse Effect. The Company has no knowledge of any federal, state or other
governmental tax deficiency, penalty or assessment which has been or might be asserted or threatened against it which would reasonably
be expected to have a Material Adverse Effect. The charges, accruals and reserves on the books of the Company in respect of any
income and corporation tax liability for any years not finally determined are adequate to meet any assessments or re-assessments
for additional income tax for any years not finally determined, except to the extent of any inadequacy that would not, singly
or in the aggregate, reasonably expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xxvii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Insurance</U>. The Company and its subsidiaries carry or are entitled to the benefits of insurance, with financially
sound and reputable insurers, in such amounts and covering such risks as is generally maintained by companies of established repute
engaged in the same or similar business, and all such insurance is in full force and effect. The Company has no reason to believe
that it or any of its subsidiaries will not be able (A) to renew its existing insurance coverage as and when such policies expire
or (B) to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now
conducted and at a cost that would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect.
Neither of the Company nor any of its subsidiaries has been denied any insurance coverage which it has sought or for which it has
applied <FONT STYLE="background-color: white">where such denial would or has resulted in a Material Adverse Effect</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xxviii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Investment Company Ac</U>t. The Company is not required, and upon the issuance and sale of the Shares as contemplated
herein and the application of the net proceeds therefrom as described in the Registration Statement, the General Disclosure Package
and the Prospectus will not be required, to register as an &ldquo;investment company&rdquo; under the Investment Company Act of
1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xxix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Absence
of Manipulation</U>. Neither the Company nor any affiliate of the Company has taken, nor will the Company or any such affiliate
take, directly or indirectly, any action which is designed, or would be expected, to cause or result in, or which constitutes,
the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any Shares or
to result in a violation of Regulation M under the 1934 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xxx)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Foreign
Corrupt Practices Act</U>. None of the Company, any of its subsidiaries or, to the knowledge of the Company, any director, officer,
agent, employee, affiliate or other person acting on behalf of the Company or any of its subsidiaries is aware of or has taken
any action, directly or indirectly, that would result in a violation by such persons of either (A) the Foreign Corrupt Practices
Act of 1977, as amended, and the rules and regulations thereunder (the &ldquo;<U>FCPA</U>&rdquo;), including, without limitation,
making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment,
promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the
giving of anything of value to any &ldquo;foreign official&rdquo; (as such term is defined in the FCPA) or any foreign political
party or official thereof or any candidate for foreign political office, in contravention of the FCPA or (B) the U.K. Bribery
Act 2010 (the &ldquo;<U>Bribery Act</U>&rdquo;), and the Company, its subsidiaries and, to the knowledge of the Company, its other
affiliates have conducted their businesses in compliance with the FCPA and the Bribery Act and have instituted and maintain policies
and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xxxi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Money Laundering Laws</U>. The operations of the Company and its subsidiaries are and have been conducted at all
times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions
Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder and
any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively,
the &ldquo;<U>Money Laundering Laws</U>&rdquo;). No action, suit or proceeding by or before any Governmental Entity involving the
Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xxxii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>OFAC</U>. None of the Company, any of its subsidiaries or, to the knowledge of the Company, any director, officer,
agent, employee, affiliate or other person acting on behalf of the Company or any of its subsidiaries is (A) an individual or entity
(&ldquo;<U>Person</U>&rdquo;) currently the subject or target of any sanctions administered or enforced by the United States Government,
including, without limitation the U.S. Department of the Treasury&rsquo;s Office of Foreign Assets Control, the United Nations
Security Council, the European Union, Her Majesty&rsquo;s Treasury, or other relevant sanctions authority (collectively, &ldquo;<U>Sanctions</U>&rdquo;),
or (B) located, organized or resident in a country or territory that is the subject of Sanctions. The Company will not, directly
or indirectly, use the proceeds of the sale of the Shares, or lend, contribute or otherwise make available such proceeds to any
of its subsidiaries, joint venture partners or other Persons, to fund any activities of or business with any Person, or in any
country or territory, that, at the time of such funding, is the subject of Sanctions or in any other manner that will result in
a violation by any Person (including any Person participating in the transaction, whether as underwriter, advisor, investor or
otherwise) of Sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xxxiii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>&nbsp;Statistical and Market-Related Data</U>. Nothing has come to the attention of the Company that has caused the
Company to believe that the statistical and market-related data included in the Registration Statement, the General Disclosure
Package or the Prospectus is not based on or derived from sources that are reliable and accurate in all material respects and,
to the extent required, the Company has obtained the written consent to the use of such data from such sources</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xxxiv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>No Commissions</U>. Neither the Company nor any of its subsidiaries are a party to any contract, agreement or
understanding with any person (other than as contemplated by this Agreement) that would give rise to a valid claim against the
Company, any of its subsidiaries or the Agent for a brokerage commission, finder&rsquo;s fee or like payment in connection with
the offering and sale of any Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xxxv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Not an Actively-Traded Security</U>. Unless the Company informs the Agent otherwise the Common Stock is not an
 &ldquo;actively-traded security&rdquo; exempted from the requirements of Rule 101 of Regulation M under the 1934 Act by subsection
(c)(1) of such rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xxxvi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Cybersecurity and Data Protection</U>. (A) There has been no security breach or incident, unauthorized access
or disclosure, or other compromise of or relating to, the Company&rsquo;s or its subsidiaries&rsquo; information technology and
computer systems, networks, hardware, software, data and databases (including the data and information of their respective patients,
customers, employees, suppliers, vendors and any third party data maintained, processed or stored by the Company or its subsidiaries,
and any such data processed or stored by third parties on behalf of the Company or its subsidiaries), equipment or technology (collectively,
 &ldquo;<U>IT Systems and Data</U>&rdquo;), (B)&nbsp;neither the Company nor its subsidiaries have been notified of, and have no
knowledge of any event or condition that would result in, any security breach or incident, unauthorized access or disclosure of
or other compromise to their IT Systems and Data and (C) the Company and its subsidiaries have implemented appropriate controls,
policies, procedures, and technological safeguards to maintain and protect the integrity, continuous operation, redundancy, disaster
recovery and security of their IT Systems and Data consistent with industry standards and practices, or as required by applicable
data protection laws, Healthcare Laws and regulatory standards, except with respect to clauses (A) and (B), for any such security
breach or incident, unauthorized access or disclosure, or other compromises, as would not, individually or in the aggregate, have
a Material Adverse Effect, or with respect to clause (C), where the failure to do so would not, individually or in the aggregate,
have a Material Adverse Effect. The Company and its subsidiaries are presently in compliance in all material respects with all
applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory
authority, internal policies and contractual obligations relating to the privacy and security of the IT Systems and Data, including
the collection, use, transfer, processing, disposal, disclosure, handling, storage and analysis of personally identifiable information,
protected health information, consumer information and other confidential information of the Company, its subsidiaries and any
third parties in their possession, and the protection of such IT Systems and Data from unauthorized use, access, misappropriation
or modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xxxvii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT></FONT><U>&nbsp;Regulatory Matters</U>. The Company and each of its subsidiaries: (a) are and have been in material compliance
with applicable health care laws, including, without limitation, the Federal Food, Drug and Cosmetic Act (21 U.S.C. &sect; 301
et seq.), the Federal Anti-kickback Statute (42 U.S.C. &sect; 1320a-7b(b)), Physician Payment Sunshine Act (42 U.S.C. &sect; 1320a-7h),
the civil False Claims Act (31 U.S.C. &sect;&sect; 3729 et seq.), the administrative False Claims Law (42 U.S.C. &sect; 1320a-7b(a)),
the Anti-Inducement Law (42 U.S.C. &sect; 1320a-7a(a)(5)), the Health Insurance Portability and Accountability Act of 1996 (42
U.S.C. &sect; 1320d et seq.), as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, the
exclusion laws, Social Security Act &sect; 1128 (42 U.S.C. &sect; 1320a-7), Medicare (Title XVIII of the Social Security Act),
Medicaid (Title XIX of the Social Security Act) and the regulations promulgated pursuant to such laws, and comparable state laws,
and all other local, state, federal, national, supranational and foreign laws, manual provisions, policies and administrative guidance
relating to the regulation of the Company and its subsidiaries (collectively, &ldquo;<U>Health Care Laws</U>&rdquo;); (b) have
not received notice of any ongoing claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action
from any Regulatory Agency or third party alleging that any product operation or activity is in material violation of any Health
Care Laws and has no knowledge that any such Regulatory Agency or third party is considering any such claim, litigation, arbitration,
action, suit, investigation or proceeding; and (c) are not a party to any corporate integrity agreement, deferred prosecution agreement,
monitoring agreement, consent decree, settlement order or similar agreements or have any reporting obligations pursuant to any
such agreement, plan or correction or other remedial measure entered into with any governmental authority. Neither the Company
nor its subsidiaries or any of their officers, directors, employees, agents or contractors has been or is currently debarred, suspended
or excluded from participation in the Medicare and Medicaid programs or any other state or federal health care program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xxxviii)
</FONT>&nbsp;&nbsp;<U>Preclinical and Clinical Studies and Tests</U>. The preclinical tests and clinical trials that are described
in, or the results of which are referred to in, the Registration Statement, the General Disclosure Package and the Prospectus,
as applicable, were and, if still pending, are being conducted in all material respects in accordance with protocols filed with
the appropriate Regulatory Agencies for each such test or trial, as the case may be, and with standard medical and scientific
research procedures and all applicable statutes, directives, rules and regulations of the Regulatory Agencies, including, without
limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder; each description of
such tests and trials, and the results thereof, contained in the Registration Statement, the General Disclosure Package and the
Prospectus, as applicable, is accurate and complete in all material respects and fairly presents the data about and derived from
such tests and trials, and the Company has no knowledge of any other studies or tests or modifications, the results of which are
inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the General
Disclosure Package and the Prospectus, as applicable; neither the Company nor its subsidiaries has received any notices or other
correspondence from any Regulatory Agency requiring the termination, suspension or modification of any clinical trials; and each
of the Company and its subsidiaries has operated and currently is in compliance in all material respects with all applicable rules
and regulations of the Regulatory Agencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(xxxix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>No Safety Notices</U>. (i) There have been no recalls, field notifications, field corrections, market withdrawals
or replacements, warnings, &ldquo;dear doctor&rdquo; letters, investigator notices, safety alerts or other notice of action relating
to an alleged lack of safety, efficacy, or regulatory compliance of the Company&rsquo;s or its subsidiaries&rsquo; products and
product candidates (&ldquo;<U>Safety Notices</U>&rdquo;), except as would not reasonably be expected to, singly or in the aggregate,
result in a Material Adverse Effect, and (ii) there are no facts that would be reasonably likely to result in (x) a Safety Notice
with respect to the Company&rsquo;s or its subsidiaries&rsquo; products and product candidates, or (y) a termination or suspension
of testing of any of the Company&rsquo;s or its subsidiaries&rsquo; products and product candidates, except, in each of cases (x)
or (y) such as would not reasonably be expected to, singly or in the aggregate, result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>Any
certificate signed by any officer or other authorized signatory of the Company and delivered to the Agent or to counsel for the
Agent shall be deemed a representation and warranty by the Company to the Agent as to the matters covered thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Sale and Delivery of Shares</U><FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>Subject
to the terms and conditions set forth herein, the Company agrees to issue and sell Shares through the Agent acting as sales agent
or directly to the Agent acting as principal from time to time. Sales of the Shares, if any, through the Agent acting as sales
agent or directly to the Agent acting as principal will be made by means of transactions that are deemed to be &ldquo;at-the-market&rdquo;
offerings as defined in Rule 415 under the 1933 Act, including block trades, ordinary brokers&rsquo; transactions on the NYSE
American or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated
prices, or by any other method permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>The
Shares are to be sold to the Agent on an agented basis on any day (other than a day on which the NYSE American is scheduled to
close prior to its regular weekday closing time) (each, a &ldquo;<U>Trading Day</U>&rdquo;) on which (i) the Company has instructed
the Agent to make such sales and (ii) the Company has satisfied its covenants and conditions specified in Sections 4 and 5 hereof.
On any Trading Day, the Company may sell Shares through the Agent and, if it determines to do so, shall instruct the Agent by
telephone (confirmed promptly by email, which confirmation will be promptly acknowledged by the Agent) as to the maximum number
of Shares to be sold on such Trading Day and the minimum price per Share at which such Shares may be sold. Subject to the terms
and conditions specified herein (including, without limitation, the accuracy of the representations and warranties of the Company
and the performance by the Company of its covenants and other obligations, contained herein and the satisfaction of the additional
conditions specified in Section 5 hereof), the Agent shall use its commercially reasonable efforts, consistent with its normal
trading and sales practices and applicable law and regulations, to sell all of the Shares so designated by the Company in accordance
with such instruction. Each of the Company and the Agent acknowledges and agrees that (A) there can be no assurance that the Agent
will be successful in selling any Shares and (B) the Agent will not incur any liability or obligation to the Company if it fails
to sell Shares for any reason other than a failure to use its commercially reasonable efforts, consistent with its normal trading
and sales practices and applicable law and regulations, to sell such Shares as required by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Company or the Agent through whom the sale of Shares are to be made as sales agent on any Trading Day may, upon
notice to the other party hereto by telephone (confirmed promptly by telecopy or email, which confirmation will be promptly acknowledged
by the receiving party), suspend the offering of Shares with respect to which the Agent is acting as sales agent for any reason
and at any time&#894; <U>provided</U>, <U>however</U>, that such suspension shall not affect or impair the parties&rsquo; respective
obligations with respect to the Shares sold, or with respect to Shares that the Company has agreed to sell, hereunder prior to
the giving of such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.9pt; text-indent: 0.5in"><FONT STYLE="color: #010000">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The gross sales price of any Shares sold pursuant to this Agreement by the Agent acting as sales agent of the Company
shall be equal to, in the discretion of the Agent but subject to the specific instructions of the Company, the market price prevailing
at the time of sale for the Shares sold by the Agent on the NYSE American or otherwise, at prices related to prevailing market
prices or at negotiated prices. The compensation payable to the Agent for sales of Shares with respect to which the Agent acts
as sales agent shall be up to 3.00% of the gross sales price for such Shares. The remaining proceeds, after further deduction for
any transaction fees, transfer taxes or similar taxes or fees imposed by any Governmental Entity or self-regulatory organization
in respect of such sales, shall constitute the net proceeds to the Company for such sales (the &ldquo;<U>Net Proceeds</U>&rdquo;).
The Agent shall notify the Company as promptly as practicable if any deduction referenced in this Section 2(d) will be made. Notwithstanding
the foregoing, in the event the Company engages the Agent as sales agent for the sale of Shares that would constitute a &ldquo;distribution&rdquo;
within the meaning of Rule 100 of Regulation M under the 1934 Act, the Company and the Agent will agree to compensation for the
Agent that is customary for such sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.9pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>If acting as sales agent hereunder, the Agent shall provide written confirmation to the Company following the close
of trading on the NYSE American on each Trading Day on which Shares are sold under this Agreement setting forth (i) the number
of Shares sold on such day, (ii) the aggregate gross sales proceeds of the Shares, (iii) the aggregate Net Proceeds to the Company
and (iv) the aggregate compensation payable by the Company to the Agent with respect to such sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Under no circumstances shall the aggregate gross sales price or number, as the case may be, of Shares offered or
sold pursuant to this Agreement, or which are the subject of instructions to the Agent as sales agent pursuant to Section 2(b)
hereof, exceed the aggregate gross sales price or number, as the case may be, of Shares (i) referred to in the preamble paragraph
of this Agreement, as reduced by prior sales of Shares under this Agreement, (ii) available for sale under the Registration Statement
or (iii) duly authorized from time to time to be issued and sold under this Agreement by the Company or approved for listing on
the NYSE American, and, in each case referred to in clause (ii) and (iii), notified to the Agent in writing. In addition, under
no circumstances shall any Shares with respect to which the Agent acts as sales agent be offered or sold, or be the subject of
instructions to the Agent as sales agent pursuant to Section 2(b) hereof, at a price lower than the minimum price therefor duly
authorized from time to time by the Company and notified to the Agent in writing. The Agent shall have no responsibility for maintaining
records with respect to Shares available for sale under the Registration Statement or for determining the aggregate gross sales
price, number or minimum price of Shares duly authorized by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>If the exemptive provisions set forth in Rule 101(c)(1) of Regulation M under the 1934 Act become satisfied with
respect to the Company or the Shares, the Company shall promptly notify the Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Settlement for sales of Shares will occur on the second business day that is also a Trading Day following the trade
date on which such sales are made, unless another date shall be agreed to in writing by the Company and the Agent (each such day,
a &ldquo;<U>Settlement Date</U>&rdquo;). On each Settlement Date for the sale of Shares through the Agent as sales agent, such
Shares shall be delivered by the Company to the Agent in book-entry form to the Agent&rsquo;s account at The Depository Trust Company
against payment by the Agent of the Net Proceeds from the sale of such Shares in same day funds delivered to an account designated
by the Company. If the Company shall default on its obligation to deliver Shares through the Agent as sales agent on any Settlement
Date, the Company shall (i) indemnify and hold the Agent harmless against any loss, claim or damage arising from or as a result
of such default by the Company and (ii) pay the Agent any commission to which it would otherwise be entitled absent such default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Notwithstanding any other provision of this Agreement, the Company shall not offer or sell, or instruct the Agent
to offer or sell, any Shares through the Agent as sales agent (and, by notice to the Agent given by telephone (confirmed promptly
by email) and shall cancel any instructions for any such offer or sale of any Shares prior to the commencement of the periods referenced
below), and the Agent shall not be obligated to make any such offer or sale of Shares, (i) during any period in which the Company
is, or could be deemed to be, in possession of material non-public information or (ii) except as provided in Section 2(j) hereof,
at any time during the period commencing on the 10<SUP>th</SUP> business day prior to the time the Company issues a press release
containing, or shall otherwise publicly announce, its earnings, revenues or other operating results for a fiscal period or periods
(each, an &ldquo;<U>Earnings Announcement</U>&rdquo;) through and including the time that is 24 hours after the time that the Company
files a Quarterly Report on Form 10-Q or an Annual Report on Form 10-K (a &ldquo;<U>Filing Time</U>&rdquo;) that includes consolidated
financial statements as of and for the same fiscal period or periods, as the case may be, covered by such Earnings Announcement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Notwithstanding clause (ii) of Section 2(i) hereof, if the Company wishes to offer or sell Shares to the Agent as
sales agent at any time during the period from and including an Earnings Announcement through and including the corresponding Filing
Time, the Company shall first (i) prepare and deliver to the Agent (with a copy to counsel for the Agent) a Current Report on Form
8-K that includes substantially the same financial and related information (together with management&rsquo;s discussion and analysis
thereof) that was included in such Earnings Announcement (other than any earnings projections and similar forward-looking data
and officers&rsquo; quotations) (each, an &ldquo;<U>Earnings 8-K</U>&rdquo;), in form and substance reasonably satisfactory to
the Agent, and, prior to its filing, obtain the written consent of the Agent to such filing (which consent shall not be unreasonably
withheld), (ii) provide the Agent with the officers&rsquo; certificate, opinions and letters of counsel and accountants&rsquo;
letter specified in Section 3(o), (p) and (q), respectively, hereof, (iii) afford the Agent the opportunity to conduct a due diligence
review in accordance with Section 3(t) hereof prior to filing such Earnings 8-K and (iv) file such Earnings 8-K with the Commission.
For purposes of clarity, the parties hereto agree that (A) the delivery of any officers&rsquo; certificate, opinion or letter of
counsel or accountants&rsquo; letter pursuant to this Section 2(j) shall not relieve the Company from any of its obligations under
this Agreement with respect to any Quarterly Report on Form 10-Q or Annual Report on Form 10-K, as the case may be, including,
without limitation, the obligation to deliver officers&rsquo; certificates, opinions and letters of counsel and accountants&rsquo;
letters as provided in Section 3(o), (p) and (q), respectively, hereof, and (B) this Section 2(j) shall in no way affect or limit
the operation of clause (i) of Section 2(i) hereof, which shall have independent application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Agent shall not have any obligation to purchase Shares as principal, whether from the Company or otherwise, unless
the Company and the Agent agree as set forth below. Shares purchased from the Company by the Agent as principal shall be made in
accordance with terms agreed upon between the Agent and the Company as evidenced by a Terms Agreement. The Agent&rsquo;s commitment
to purchase Shares from the Company as principal shall be deemed to have been made on the basis of the accuracy of the representations
and warranties of the Company, and performance by the Company of its covenants and other obligations, herein contained and shall
be subject to the terms and conditions herein set forth. At the time of each Terms Agreement, the Agent shall specify the requirements,
if any, for the officers&rsquo; certificate, opinions and letters of counsel and accountants&rsquo; letter pursuant to Section
3(o), (p) and (q), respectively, hereof. In the event of a conflict between the terms of this Agreement and a Terms Agreement,
the terms of such Terms Agreement shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Covenants<FONT STYLE="font-family: Times New Roman, Times, Serif">. The Company agrees with the Agent:</FONT></U></P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Compliance with Securities Regulations and Commission Requests</I>. The Company, subject to Sections 3(b) and
3(c) hereof, will use its commercially reasonable efforts to comply with the requirements of Rule 430B, and will promptly notify
the Agent (i) when any post-effective amendment to the Registration Statement or any new registration statement relating to the
Shares shall become effective or any amendment or supplement to the Prospectus shall have been filed (other than an amendment or
supplement providing solely for the determination of the terms of an offering of securities unless related to an offering of Shares,
as to which the Company will only be obligated to notify the Agent), (ii) of the receipt of any comments from the Commission, (iii)
of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus,
including any document incorporated by reference therein, or for additional information, (iv) of the issuance by the Commission
of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto or any notice
of objection to the use of the Registration Statement or any post-effective amendment thereto pursuant to Rule 401(g)(1) or of
the issuance of any order preventing or suspending the use of any preliminary prospectus or the Prospectus or any amendment or
supplement thereto, or of the suspension of the qualification of any Shares for offering or sale in any jurisdiction, or of the
initiation or threatening of any proceedings for any of such purposes or of any examination pursuant to Section 8(d) or 8(e) of
the 1933 Act concerning the Registration Statement and (v) if the Company becomes the subject of a proceeding under Section 8A
of the 1933 Act in connection with any offering of Shares. In connection with a Terms Agreement, the Company will prepare and file
with the Commission, subject to Section 3(c) hereof, a pricing supplement with respect to the offer and sale of Shares covered
by such Terms Agreement. The Company will effect all filings required under Rule 424(b), in the manner and within the time period
required by Rule 424(b) (without reliance on Rule 424(b)(8)), and will take such steps as it deems necessary to ascertain promptly
whether the form of prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the event
that it was not, it will promptly file such prospectus. The Company will make every reasonable effort to prevent the issuance of
any stop, prevention or suspension order and, if any such order is issued, to obtain the lifting thereof at the earliest possible
moment. In the event of any issuance of a notice of objection, by the Commission, the Company shall take all necessary action to
permit offers and sales of Shares by or through the Agent, including, without limitation, amending the Registration Statement or
filing a new shelf registration statement relating thereto. The Company shall pay the required Commission filing fees relating
to the Shares prior to the time the initial Prospectus Supplement is filed with the Commission or the time any subsequent Prospectus
Supplement that increases the gross offering price or number of Shares that may offered and sold under this Agreement from that
referenced in the immediately preceding Prospectus Supplement filed with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Continued Compliance with Securities Laws</I>. The Company will use its commercially reasonable efforts to comply
with the 1933 Act, the 1933 Act Regulations, the 1934 Act and the 1934 Act Regulations so as to permit the completion of sales
of Shares as contemplated in this Agreement and in the Registration Statement, the General Disclosure Package and the Prospectus.
If any event shall occur or condition shall exist as a result of which it is necessary, in the opinion of counsel for the Agent
or counsel for the Company, to (i) amend the Registration Statement in order that the Registration Statement will not include an
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein not misleading, (ii) amend or supplement the General Disclosure Package or the Prospectus in order that the General Disclosure
Package or the Prospectus, as the case may be, will not include any untrue statement of a material fact or omit to state a material
fact necessary in order to make the statements therein not misleading in the light of the circumstances existing at the time it
is delivered to a purchaser or (iii) amend the Registration Statement or amend or supplement the General Disclosure Package or
the Prospectus, as the case may be, including, without limitation, the filing of any document incorporated by reference therein,
in order to comply with the requirements of the 1933 Act, the 1933 Act Regulations, the 1934 Act or the 1934 Act Regulations, the
Company will promptly (A) give the Agent written notice of such event or condition, (B) prepare any amendment or supplement as
may be necessary to correct such statement or omission or to comply with such requirements and, a reasonable amount of time prior
to any proposed filing or use, furnish the Agent with copies of any such amendment or supplement and (C) file with the Commission
any such amendment or supplement and use its commercially reasonable efforts to have any amendment to the Registration Statement
declared effective by the Commission as soon as practicable if the Company is no longer eligible to file a shelf registration statement;
provided, however, that, during the period in which there is any sales instruction pending under this Agreement, the Company shall
not file or use any such amendment or supplement to which the Agent or counsel for the Agent shall reasonably object.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Filing or Use of Amendments and Supplements</I>. The Company will give the Agent written notice of its intention
to file or use (i) any amendment to the Registration Statement or any amendment or supplement to the General Disclosure Package
or the Prospectus (other than an amendment or supplement thereto relating solely to the offering of securities unless related to
an offering of Shares), whether pursuant to the 1933 Act, the 1934 Act or otherwise, (ii) any new Prospectus Supplement that includes
information in addition to the information referred to in Section 3(n) hereof or (iii) a pricing supplement disclosing the offer
and sale of Shares covered by a Terms Agreement, will furnish the Agent with copies of any such document a reasonable amount of
time prior to such proposed filing or use, as the case may be, and will not file or use any such document to which the Agent or
counsel for the Agent shall reasonably object.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Delivery of Registration Statements</I>. The Company has furnished or will deliver to the Agent and counsel for
the Agent, without charge, signed copies of the Registration Statement as originally filed and each amendment thereto (including
exhibits filed therewith or incorporated by reference therein and documents incorporated or deemed to be incorporated by reference
therein) and signed copies of all consents and certificates of experts<FONT STYLE="background-color: white">; provided, however
that the Company shall not be required to furnish any document to the Agent or its counsel to the extent such document is available
on EDGAR</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Split-Segment; Name: 1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(e)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Delivery of Prospectuses</I>. The Company will furnish to the Agent, without charge, upon execution of this Agreement
and thereafter during the period in which a prospectus is (or, but for the exception afforded by Rule 172 of the 1933 Act Regulations
(&ldquo;<U>Rule 172</U>&rdquo;), would be) required by the 1933 Act to be delivered in connection with any offer or sale of Shares,
such number of copies of the Prospectus (as amended or supplemented) as the Agent may reasonably request. The Company will also
furnish, upon request of the Agent, copies of the Prospectus (as amended or supplemented) to each exchange or market on which sales
of Shares were made as may be required by the rules and regulations of such exchange or market. The Prospectus and any amendments
or supplements thereto furnished in accordance with this Section 3(e) will be identical to the electronically transmitted copies
thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(f)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Reporting Requirements</I>. The Company, during the period in which a prospectus is (or, but for the exception
afforded by Rule 172, would be) required by the 1933 Act to be delivered in connection with any offer or sale of Shares, will file
all documents required to be filed with the Commission pursuant to the 1934 Act within the time periods prescribed by, and meeting
the requirements of, the 1934 Act and the 1934 Act Regulations. Additionally, the Company shall report the use of the net proceeds
from the sale of any Shares as may be required under the 1933 Act and the 1933 Act Regulations, including, if applicable, Rule
463 of the 1933 Act Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(g)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Blue Sky Qualifications</I>. The Company will cooperate with the Agent to qualify the Shares for offering and
sale under the applicable securities laws of such states and non-U.S. jurisdictions as the Agent, may, from time to time, designate
and to maintain such qualifications in effect so long as required to complete the sale of the Shares contemplated by this Agreement&#894;
<U>provided</U>, <U>however</U>, that the Company shall not be obligated to file any general consent to service of process or to
qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject
itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Earnings Statement</I>. The Company will timely file such reports pursuant to the 1934 Act as are necessary in
order to make generally available to its securityholders as soon as practicable an earnings statement for the purposes of, and
to provide to the Agent with the benefits contemplated by, the last paragraph of Section 11(a) of the 1933 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Use of Proceeds</I>. The Company will use the net proceeds received by it from the sale of the Shares pursuant
to this Agreement in the manner specified in the Registration Statement, the General Disclosure Package and the Prospectus under
 &ldquo;Use of Proceeds.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Listing</I>. The Company will use its reasonable best efforts to effect and maintain the listing of the Shares
on, and satisfy the requirements of, the NYSE American.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Notice of Certain Actions</I>. <FONT STYLE="background-color: white">During the period beginning on the commencement
of an offering of Shares under this Agreement and ending on the applicable Settlement Date, t</FONT>he Company will not, without
the prior written consent of the Agent, unless it gives the Agent at least three business days&rsquo; prior written notice, (i)
directly or indirectly offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract
to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of any shares of Common Stock or any securities
convertible into or exercisable or exchangeable for shares of Common Stock or file any registration statement under the 1933 Act
with respect to any of the foregoing or (ii) enter into any swap or any other agreement or transaction that transfers, in whole
or in part, directly or indirectly, the economic consequence of ownership of the Common Stock, whether any such swap, agreement
or transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or such other securities, in
cash or otherwise. The foregoing sentence shall not apply to (A) Shares to be sold hereunder, (B) any shares of Common Stock issued
by the Company upon the exercise of an option or warrant or the conversion of a security outstanding on the date hereof and referred
to in the Registration Statement, the General Disclosure Package and the Prospectus, (C) any shares of Common Stock issued or options
to purchase Common Stock, granted pursuant to existing employee benefit plans of the Company referred to in the Registration Statement,
the General Disclosure Package and the Prospectus (D) any shares of Common Stock issued pursuant to any non-employee director stock
plan or dividend reinvestment plan referred to in the Registration Statement, the General Disclosure Package and the Prospectus
or (E) <FONT STYLE="background-color: white">any shares of Common Stock, or securities convertible into or exercisable for Common
Stock, offered and sold in a privately negotiated transaction to vendors, customers, strategic partners or potential strategic
partners or other investors conducted in a manner so as not to be integrated with the offering of Common Stock hereby, <U>provided</U>
that such shares of Common Stock and the shares of Common Stock underlying such securities upon such conversion or exercise, in
aggregate, do not exceed 5% of the Common Stock outstanding immediately prior to giving effect to such conversion or exercise</FONT>.
Upon receipt of any written notice contemplated above, the Agent may suspend its activity under this Agreement for such period
of time as deemed reasonably appropriate by the Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Options: NewSection; Value: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Issuer Free Writing Prospectuses</I>. At all times during such period as the Prospectus is required by law to
be delivered in connection with sales of the Shares, the Company agrees that, unless it obtains the prior written consent of the
Agent, it will not make any offer relating to the Shares that would constitute an Issuer Free Writing Prospectus or that would
otherwise constitute a &ldquo;free writing prospectus,&rdquo; or a portion thereof, required to be filed by the Company with the
Commission or retained by the Company under Rule 433. The Company represents that it has treated or agrees that it will treat each
such free writing prospectus consented to by the Agent as an &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433,
and that it will comply with the applicable requirements of Rule 433 with respect thereto, including timely filing with the Commission
where required, legending and record keeping. If at any time following the issuance of an Issuer Free Writing Prospectus any event
shall occur or condition shall exist as a result of which such Issuer Free Writing Prospectus conflicted or would conflict with
the information contained in the Registration Statement, any preliminary prospectus or the Prospectus or included or would include
an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the
Agent and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such
conflict, untrue statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>No Stabilization or Manipulation</I>. The Company agrees that neither it nor any affiliate of the Company will
take, directly or indirectly, any action which is designed, or would be expected, to cause or result in, or which constitutes,
the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any Shares or
to result in a violation of Regulation M under the 1934 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Update of Activity under this Agreement</I>. The Company shall disclose (i) in each Annual Report on Form 10-K
or Quarterly Report on Form 10-Q filed by the Company in respect of any fiscal quarterly period (which, in the case of an Annual
Report on Form 10-K, would mean the last quarterly period of the fiscal year) in which sales of Shares were made by or through
the Agent under this Agreement (each date on which any such document or amendment thereto is filed, a &ldquo;<U>Company Periodic
Report Date</U>&rdquo;), or (ii) to the extent required by applicable law and/or interpretations of the Commission, in Prospectus
Supplements for each such fiscal quarterly period, the number of Shares sold by or through the Agent under this Agreement during
such fiscal quarterly period, the net proceeds received by the Company and the aggregate compensation paid by the Company to the
Agent with respect to such sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Delivery of Future Officers&rsquo; Certificates</I>. Upon commencement of the offering of Shares under this Agreement,
(A) each time Shares are delivered to the Agent as principal on a Settlement Date, (B) promptly after each (i) date on which the
Registration Statement shall be amended or a new registration statement relating to the Shares shall become effective or the Prospectus
shall be amended or supplemented (other than (1) by an amendment or supplement providing solely for the determination of the terms
of securities, including the Shares, (2) in connection with the filing of a Prospectus Supplement that contains solely the information
referred to in Section 3(n) hereof, or (3) in connection with the filing of any Current Report on Form 8-K (other than an Earnings
8-K and any other Current Report on Form 8-K which contains financial statements, supporting schedules or other financial data,
including any Current Report on Form 8-K under Item 2.02 of such form, that is considered &ldquo;filed&rdquo; under the 1934 Act)
(each such date, a &ldquo;<U>Registration Statement Amendment Date</U>&rdquo;), (ii) date on which an Earnings 8-K shall be filed
with the Commission as contemplated by Section 2(j) hereof (a &ldquo;<U>Company Earnings Report Date</U>&rdquo;) and (iii) Company
Periodic Report Date, and (C) promptly after each reasonable request by the Agent (each date of any such request by the Agent,
a &ldquo;<U>Request Date</U>&rdquo;), the Company will furnish or cause to be furnished to the Agent an officers&rsquo; certificate,
dated such Settlement Date, such Registration Statement Amendment Date, such Company Earnings Report Date, such Company Periodic
Report Date or such Request Date, as the case may be, in form and substance reasonably satisfactory to the Agent, to the effect
that the statements contained in the officers&rsquo; certificate referred to in Section 5(f) hereof that was last furnished to
the Agent are true and correct as of the date of such certificate as though made at and as of the date of such certificate (except
that such statements shall be deemed to relate to the Registration Statement, the General Disclosure Package and the Prospectus
as amended and supplemented at the date of such certificate) or, in lieu of such certificate, a certificate of the same tenor as
the certificate referred to in Section 5(f) hereof but modified as necessary to relate to the Registration Statement, the General
Disclosure Package and the Prospectus as amended and supplemented at the date of such certificate. As used in this Section 3(o),
to the extent there shall be a sale of Shares on or following any Registration Statement Amendment Date, Company Earnings Report
Date, Company Periodic Report Date or Request Date, &ldquo;promptly&rdquo; shall be deemed to be at or prior to the Applicable
Time for such sale. <FONT STYLE="background-color: white">The requirement to provide a certificate under this paragraph shall be
waived for any </FONT>Registration Statement Amendment Date, Company Earnings Report Date, or Company Periodic Report Date <FONT STYLE="background-color: white">on
which there is not an offering of Shares under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Delivery of Future Opinions and Letters of Counsel</I>. Upon commencement of the offering of Shares under this
Agreement, (A) each time Shares are delivered to the Agent as principal on a Settlement Date and (B) promptly after each Registration
Statement Amendment Date, Company Earnings Report Date, Company Periodic Report Date or Request Date, the Company will furnish
or cause to be furnished to the Agent the written opinions and letters of each of counsel for the Company (who shall be reasonably
acceptable to the Agent) and counsel for the Agent, dated such Settlement Date, such Registration Statement Amendment Date, such
Company Earnings Report Date, such Company Periodic Report Date or such Request Date, as the case may be, in form and substance
reasonably satisfactory to the Agent, of the same tenor as the respective opinions and letters referred to in Sections 5(b) and
5(c), as applicable, hereof but modified as necessary to relate to the Registration Statement, the General Disclosure Package and
the Prospectus as amended and supplemented to the date of such opinion and letter in lieu of any such opinion and letter, counsel
last furnishing such opinion and letter to the Agent shall furnish the Agent with a letter substantially to the effect that the
Agent may rely on such counsel&rsquo;s last opinion and letter to the same extent as though each were dated the date of such letter
authorizing reliance (except that statements in such last opinion and letter shall be deemed to relate to the Registration Statement,
the General Disclosure Package and the Prospectus as amended and supplemented to the date of such letter authorizing reliance).
As used in this Section 3(p), to the extent there shall be a sale of Shares on or following any Registration Statement Amendment
Date, Company Earnings Report Date, Company Periodic Report Date or Request Date, &ldquo;promptly&rdquo; shall be deemed to be
at or prior to the Applicable Time for such sale. <FONT STYLE="background-color: white">The requirement to provide the opinions
and letters under this paragraph shall be waived for any </FONT>Registration Statement Amendment Date, Company Earnings Report
Date, or Company Periodic Report Date <FONT STYLE="background-color: white">on which there is not an offering of Shares under this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Delivery of Future Accountants&rsquo; Letters</I>. Upon commencement of the offering of Shares under this Agreement,
(A) each time Shares are delivered to the Agent as principal on a Settlement Date and (B) promptly after each Registration Statement
Amendment Date, Company Earnings Report Date, Company Periodic Report Date or Request Date, the Company will cause its independent
accountants to furnish to the Agent a letter, dated such Settlement Date, such Registration Statement Amendment Date, such Company
Earnings Report Date, such Company Periodic Report Date or such Request Date, as the case may be, in form and substance reasonably
satisfactory to the Agent, of the same tenor as the letter referred to in Section 5(d) hereof but modified as necessary to relate
to the Registration Statement, the General Disclosure Package and the Prospectus as amended and supplemented to the date of such
letter. As used in this paragraph, to the extent there shall be a sale of Shares on or following any Registration Statement Amendment
Date, Company Earnings Report Date, Company Periodic Report Date or Request Date, &ldquo;promptly&rdquo; shall be deemed to be
at or prior to the Applicable Time for such sale. <FONT STYLE="background-color: white">The requirement to provide the letter under
this paragraph shall be waived for any </FONT>Registration Statement Amendment Date, Company Earnings Report Date, or Company Periodic
Report Date <FONT STYLE="background-color: white">on which there is not an offering of Shares under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(r)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Trading in the Common Stock</I>. The Company consents to the Agent trading in the Company&rsquo;s Common Stock
for its own account and for the account of its clients at the same time as sales of Shares occur pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(s)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Non-Consummation Offer</I>. If, to the knowledge of the Company, any filing required by Rule 424 in connection
with an offering of Shares shall not have been made or the representations and warranties of the Company contained in this Agreement
shall not be true and correct on the applicable Settlement Date, the Company will offer to any person who has agreed to purchase
Shares from or through the Agent the right to refuse to purchase and pay for such Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(t)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Due Diligence Review</I>. The Company will cooperate with any due diligence review reasonably requested by the
Agent or counsel for the Agent, fully and in a timely manner, in connection with offers and sales of Shares from time to time,
including, without limitation, and upon reasonable notice, providing information and making available documents and appropriate
corporate officers, during regular business hours and at the Company&rsquo;s principal offices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(u)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Renewal Deadline</I>. If, immediately prior to the third anniversary of the initial effective date of the Registration
Statement (the &ldquo;<U>Renewal Deadline</U>&rdquo;), this Agreement is still in effect or any Shares purchased by the Agent as
principal remain unsold, the Company will, prior to the Renewal Deadline, (i) promptly notify the Agent and (ii) promptly file,
if it is eligible to do so, an automatic shelf registration statement relating to the Shares, in a form and substance satisfactory
to the Agent. If, at the time the Company intends to file such an automatic shelf registration statement, it is not eligible to
do so, the Company will, prior to the Renewal Deadline, (i) promptly notify the Agent, (ii) promptly file a new shelf registration
statement on the proper form relating to the Shares, in a form and substance satisfactory to the Agent, (iii) use its commercially
reasonable efforts to cause such new shelf registration statement to be declared effective within 90 days after the Renewal Deadline
and (iv) promptly notify the Agent of such effectiveness. The Company will take all other action necessary or appropriate to permit
the offering and sale of the Shares to continue as contemplated in the expired Registration Statement. References herein to the
 &ldquo;Registration Statement&rdquo; shall include such new automatic shelf registration statement or such new shelf registration
statement, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Ceasing Eligibility For Use of Shelf Registration Statement Form</I>. If, at any time, during the term of this
Agreement or otherwise when Shares purchased by the Agent as principal remain unsold, the Company receives a notice from the Commission
pursuant to Rule 401(g)(1) or otherwise ceases to be eligible to use the shelf registration statement form, the Company will (i)
promptly notify the Agent, (ii) promptly file a new registration statement or post-effective amendment on the proper form relating
to such Shares, in form and substance satisfactory to the Agent, (iii) use its commercially reasonable efforts to cause such new
registration statement or post-effective amendment to be declared effective as soon as practicable and (iv) promptly notify the
Agent of such effectiveness. The Company will take all other action necessary or appropriate to permit the offering and sale of
the Shares to continue as contemplated in the Registration Statement that was the subject of the Rule 401(g)(1) notice or for which
the Company has otherwise become ineligible. References herein to the &ldquo;Registration Statement&rdquo; shall include such new
registration statement or post-effective amendment, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Payment of Expenses</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Expenses</I>. The Company will pay or cause to be paid all expenses incident to the performance of the Company&rsquo;s
obligations under this Agreement, including (i) the preparation, printing and filing of the Registration Statement (including financial
statements and exhibits) as originally filed and each amendment thereto, (ii) the preparation, printing and delivery to the Agent
of copies of any preliminary prospectus, any Issuer Free Writing Prospectus and the Prospectus and any amendments or supplements
thereto and any costs associated with electronic delivery of any of the foregoing by the Agent to investors, (iii) the preparation,
issuance and delivery of the certificates for the Shares, including any stock or other transfer taxes and any stamp or other duties
payable upon the sale, issuance or delivery by the Company of the Shares to the Agent, (iv) the fees and disbursements of the Company&rsquo;s
counsel, accountants and other advisors, (v) the qualification of the Shares under securities laws in accordance with the provisions
of Section 3(g) hereof, (vi) the fees and expenses of any transfer agent or registrar for the Shares, (vii) the costs and expenses
of the Company relating to investor presentations on any &ldquo;road show&rdquo; undertaken in connection with the marketing of
the Shares, (viii) the filing fees incident to, and the reasonable fees and disbursements of counsel for the Agent in connection
with, the review by FINRA of the terms of sales of Shares in an amount not to exceed $10,000, (ix) the fees and expenses incurred
in connection with the listing of the Shares on the NYSE American, (x) the reasonable documented out-of-pocket expenses of the
Agent, including the reasonable fees, disbursements and expenses of counsel for the Agent in an amount not to exceed $75,000 in
connection with this Agreement and the Registration Statement and ongoing services in connection with the transactions contemplated
hereunder, and (xi) the costs and expenses (including, without limitation, any damages or other amounts payable in connection with
legal or contractual liability) associated with the reforming of any contracts for the sale of Shares caused by a breach of the
representation contained in the second sentence of Section 1(a)(ii) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions
of Agent&rsquo;s Obligations.</U> The obligations of the Agent hereunder are subject to the accuracy of the representations and
warranties of the Company contained herein or in certificates of any officer of the Company or any of its subsidiaries delivered
pursuant to the provisions hereof at each Representation Date, to the performance by the Company of its covenants and other obligations
hereunder, and to the following further conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Effectiveness of Registration Statement and Filing of Prospectus</I>. The Company shall have filed the Registration
Statement with the Commission not earlier than three years prior to the date hereof and the Registration Statement declared effective
by the Commission on April 12, 2019. The Company shall have filed with the Commission the Prospectus on or prior to the date of
this Agreement and any subsequent Base Prospectus or Prospectus Supplement prior to any Applicable Time and related Settlement
Date, as applicable, in each case in the manner and within the time period required by Rule 424(b), and each Issuer Free Writing
Prospectus, if any, in the manner and within the time period required by Rule 433. No stop order suspending the effectiveness of
the Registration Statement or any post-effective amendment thereto has been issued under the 1933 Act, no notice of objection of
the Commission to the use of the Registration Statement or any post-effective amendment thereto pursuant to Rule 401(g)(1) has
been received by the Company, no order preventing or suspending the use of any preliminary prospectus or the Prospectus or any
amendment or supplement thereto has been issued and no proceedings for any of those purposes have been instituted or are pending
or, to the Company&rsquo;s knowledge, contemplated. The Company shall have complied with any and all requests for additional information
on the part of the Commission to the reasonable satisfaction of the Agent. The Company shall have paid the required Commission
filing fees relating to the Shares as specified in Section 3(a) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Opinion of Counsel for the Agent</I>. On the date of this Agreement, the Agent shall have received the favorable
written opinion or opinions of Shearman &amp; Sterling LLP, counsel for the Agent, dated such date, with respect to such matters
as the Agent may reasonably request. In giving such opinion or opinions, such counsel may rely, as to all matters governed by the
laws of jurisdictions other than the laws of the State of New York, the General Corporation Law of the State of Delaware and the
federal securities laws of the United States, upon the opinions of counsel satisfactory to the Agent. Such counsel may also state
that, insofar as such opinion involves factual matters, they have relied, to the extent they deem proper, upon certificates of
officers and other representatives of the Company and its subsidiaries and certificates of public officials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Opinions of Counsel for the Company</I>. On the date of this Agreement, the Agent shall have received the favorable
written opinion or opinions of (i) Mayer Brown LLP, New York counsel for the Company, dated such date, to the effect set forth
in <U>Exhibit A</U> hereto and to such further effect as the Agent may reasonably request; (ii) Horn &amp; Co. Law Offices, Israeli
counsel for the Company, dated such date, to the effect set forth in <U>Exhibit B</U> hereto and to such further effect as the
Agent may reasonably request and (iii) Ehrlich &amp; Fenster, special intellectual property counsel for the Company, dated such
date, to the effect set forth in <U>Exhibit C</U> hereto and to such further effect as the Agent may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Accountants&rsquo; Letter</I>. On the date of this Agreement, the Agent shall have received a letter from Kesselman
 &amp; Kesselman, a member of PricewaterhouseCoopers International Limited, dated such date, in form and substance satisfactory
to the Agent, containing statements and information of the type ordinarily included in accountants&rsquo; &ldquo;comfort letters&rdquo;
to underwriters with respect to the financial statements and other financial information included in the Registration Statement,
the General Disclosure Package and the Prospectus or any amendment or supplement thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Officer&rsquo;s Certificate on Size of ATM Program</I>. On the date of this Agreement, the Company shall have
furnished to the Agent a certificate of an executive officer of the Company, dated such date, in a form satisfactory to the Agent,
stating the minimum gross sales price per share for sales of Shares pursuant to this Agreement and the maximum number of Shares
that may be issued and sold pursuant to this Agreement or, alternatively, the maximum gross proceeds from such sales, as duly authorized
by the Company&rsquo;s board of directors or a duly authorized committee thereof, and specify the number of Shares that have been
approved for listing, subject to official notice of issuance, on the NYSE American.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Officers&rsquo; Certificate for the Company</I>. On the date of this Agreement, there shall not have been, since
the date of the latest audited financial statements included in the Registration Statement, the General Disclosure Package and
the Prospectus or since the respective dates as of which information is given in the Registration Statement, the General Disclosure
Package and the Prospectus, any Material Adverse Change, and the Agent shall have received a certificate of the Chief Executive
Officer or President of the Company and of the Chief Financial Officer or Chief Accounting Officer of the Company, dated such date,
to the effect that (A) there has been no such Material Adverse Change, (B) the representations and warranties of the Company in
this Agreement are true and correct with the same force and effect as though expressly made on and as of such date, (C) the Company
has complied with all agreements and satisfied all conditions on its part to be performed or satisfied on or prior to such date
and (D) no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been
issued under the 1933 Act, no notice of objection of the Commission to the use of the Registration Statement or any post-effective
amendment thereto pursuant to Rule 401(g)(1) has been received by the Company, no order preventing or suspending the use of any
preliminary prospectus or the Prospectus or any amendment or supplement thereto has been issued and no proceedings for any of those
purposes have been instituted or are pending or, to their knowledge, contemplated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Listing</I>. The Shares shall have been approved for listing, subject to official notice of issuance, on the NYSE
American.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Additional Documents</I>. On the date of this Agreement, counsel for the Agent shall have been furnished with
such documents and opinions as they may require for the purpose of enabling them to render the opinions or make the statements
requested by the Agent, or in order to evidence the accuracy of any of the representations or warranties, or the fulfillment of
any of the covenants, obligations or conditions, contained herein&#894; and all proceedings taken by the Company in connection
with the issuance and sale of the Shares as contemplated herein shall be satisfactory in form and substance to the Agent and counsel
for the Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.9pt; text-indent: 0.5in"><FONT STYLE="color: #010000">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Termination of this Agreement</I>. If any condition specified in this Section 5 shall not have been fulfilled
when and as required to be fulfilled, this Agreement may be terminated by the Agent by notice to the Company at any time, and any
such termination shall be without liability of any party to any other party except the provisions of Sections 1, 3(h), 4, 6, 7,
8, 10, 12, 13, 14, 15 and 16 hereof shall remain in full force and effect notwithstanding such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.9pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Indemnification.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Indemnification of the Agent</I>. The Company agrees to indemnify and hold harmless the Agent, its affiliates
(as such term is defined in Rule 501(b) of the 1933 Act Regulations (each, an &ldquo;<U>Affiliate</U>&rdquo;)), selling agents,
officers, directors and each person, if any, who controls the Agent within the meaning of Section 15 of the 1933 Act or Section
20 of the 1934 Act as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>against any and all loss, liability, claim, damage and expense whatsoever, as incurred, arising out of any untrue
statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto), including
any information deemed to be a part thereof pursuant to Rule 430B, or the omission or alleged omission therefrom of a material
fact required to be stated therein or necessary to make the statements therein not misleading or arising out of any untrue statement
or alleged untrue statement of a material fact included (A) in any preliminary prospectus, any Issuer Free Writing Prospectus,
the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) or (B) in any materials or information
provided to investors by, or with the approval of, the Company in connection with the marketing of any offering of Shares (&ldquo;<U>Marketing
Materials</U>&rdquo;), including any roadshow or investor presentations made to investors by the Company (whether in person or
electronically), or the omission or alleged omission in any preliminary prospectus, any Issuer Free Writing Prospectus, the General
Disclosure Package or the Prospectus (or any amendment or supplement thereto) or in any Marketing Materials of a material fact
necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading&#894;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>against any and all loss, liability, claim, damage and expense whatsoever, as incurred, to the extent of the aggregate
amount paid in settlement of any litigation, or any investigation or proceeding by any Governmental Entity, commenced or threatened,
or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission&#894;
<U>provided</U> that (subject to Section 6(d) below) any such settlement is effected with the written consent of the Company&#894;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>against any and all expense whatsoever, as incurred (including the fees and disbursements of counsel chosen by the
Agent), reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding
by any Governmental Entity, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission,
or any such alleged untrue statement or omission, to the extent that any such expense is not paid under (i) or (ii) above&#894;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>provided</U>, <U>however</U>, that this indemnity agreement
shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue statement or omission
or alleged untrue statement or omission made in the Registration Statement (or any amendment thereto), including any information
deemed to be a part thereof pursuant to Rule 430B, or in the General Disclosure Package or the Prospectus (or any amendment or
supplement thereto), in each case in reliance upon and in conformity with information furnished to the Company by the Agent in
writing expressly for use therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Indemnification of Company, Directors and Officers</I>. The Agent agrees to indemnify and hold harmless the Company,
its directors, each of its officers who signed the Registration Statement, and each person, if any, who controls the Company within
the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act against loss, liability, claim, damage and expense described
in the indemnity contained in Section 6(a) hereof, as incurred, but only with respect to untrue statements or omissions, or alleged
untrue statements or omissions, made in the Registration Statement (or any amendment thereto), including any information deemed
to be a part thereof pursuant to Rule 430B, or in the General Disclosure Package or the Prospectus (or any amendment or supplement
thereto), in reliance upon and in conformity with the information furnished to the Company by the Agent in writing expressly for
use therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Actions against Parties&#894; Notification</I>. Each indemnified party shall give notice as promptly as reasonably
practicable to each indemnifying party of any action commenced against it in respect of which indemnity may be sought hereunder,
but failure to so notify an indemnifying party shall not relieve such indemnifying party from any liability hereunder to the extent
it is not materially prejudiced as a result thereof and in any event shall not relieve it from any liability which it may have
otherwise than on account of this indemnity agreement. In the case of parties indemnified pursuant to Section 6(a) hereof, counsel
for the indemnified parties shall be selected by the Agent, and, in the case of parties indemnified pursuant to Section 6(b) hereof,
counsel for the indemnified parties shall be selected by the Company. An indemnifying party may participate at its own expense
in the defense of any such action&#894; <U>provided</U>, <U>howeve</U>r, that counsel for the indemnifying party shall not (except
with the prior written consent of the indemnified party) also be counsel for the indemnified party. In no event shall the indemnifying
parties be liable for fees and expenses of more than one counsel (in addition to any local counsel) separate from their own counsel
for all indemnified parties in connection with any one action or separate but similar or related actions in the same jurisdiction
arising out of the same general allegations or circumstances. No indemnifying party shall, without the prior written consent of
the indemnified parties, settle or compromise or consent to the entry of any judgment with respect to any litigation, or any investigation
or proceeding by any Governmental Entity, commenced or threatened, or any claim whatsoever in respect of which indemnification
or contribution could be sought under this Section 6 or Section 7 hereof (whether or not the indemnified parties are actual or
potential parties thereto), unless such settlement, compromise or consent (i) includes an unconditional release of each indemnified
party from all liability arising out of such litigation, investigation, proceeding or claim, and (ii) does not include a statement
as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><I>Settlement without Consent if Failure to Reimburse</I>. If at any time an indemnified party shall have requested
an indemnifying party to reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that
it shall be liable for any settlement of the nature contemplated by Section 6(a)(ii) hereof effected without its written consent
if (i) such settlement is entered into more than 90 days after receipt by such indemnifying party of the aforesaid request, (ii)
such indemnifying party shall have received notice of the terms of such settlement at least 60 days prior to such settlement being
entered into and (iii) such indemnifying party shall not have reimbursed such indemnified party in accordance with such request
prior to the date of such settlement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 7. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Contribution</U>.
 &nbsp;If the indemnification provided for in Section 6 hereof is for any reason unavailable or insufficient to hold harmless an indemnified
party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying party shall
contribute to the aggregate amount of such losses, liabilities, claims, damages and expenses incurred by such indemnified party,
as incurred, (i) in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand,
and the Agent, on the other hand, from the applicable offering of Shares or (ii) if the allocation provided by clause (i) is not
permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause
(i) above but also the relative fault of the Company, on the one hand, and the Agent, on the other hand, in connection with the
statements or omissions which resulted in such losses, liabilities, claims, damages or expenses, as well as any other relevant
equitable considerations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The relative benefits received by the Company,
on the one hand, and the Agent, on the other hand, in connection with the applicable offering of Shares shall be deemed to be in
the same proportion as the total net proceeds from such offering (before deducting expenses) received by the Company, on the one
hand, bear to the total commissions or underwriting discounts received by the applicable Agent, on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The relative fault of the Company, on the
one hand, and the Agent, on the other hand, shall be determined by reference to, among other things, whether any such untrue or
alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied
by the Company or by the Agent and the parties&rsquo; relative intent, knowledge, access to information and opportunity to correct
or prevent such statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company and the Agent agree that it
would not be just and equitable if contribution pursuant to this Section 7 were determined by pro rata allocation or by any other
method of allocation which does not take account of the equitable considerations referred to above in this Section 7. The aggregate
amount of losses, liabilities, claims, damages and expenses incurred by an indemnified party and referred to above in this Section
7 shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in investigating, preparing
or defending against any litigation, or any investigation or proceeding by any Governmental Entity, commenced or threatened, or
any claim whatsoever based upon any such untrue or alleged untrue statement or omission or alleged omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Notwithstanding the provisions of this Section
7, the Agent shall not be required to contribute any amount in excess of the total commissions or underwriting discounts received
by the Agent in connection with Shares placed or underwritten by it for sale to the public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No person guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the 1933 Act) shall be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For purposes of this Section 7, each person,
if any, who controls the Agent within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act and the Agent&rsquo;s
Affiliates, selling agents, officers and directors shall have the same rights to contribution as the Agent and each director of
the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company
within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act shall have the same rights to contribution as the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Representations, Warranties and Agreements to Survive</U><FONT STYLE="font-family: Times New Roman, Times, Serif">.&nbsp;
All representations, warranties and agreements contained in this Agreement or in certificates of officers of the Company or any
of its subsidiaries submitted pursuant hereto, shall remain operative and in full force and effect regardless of (i) any investigation
made by or on behalf of the Agent or its Affiliates, selling agents, officers, directors or any person controlling the Agent or
the Company or its officers, or any person controlling the Company and (ii) delivery of and payment for the Shares. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination</U><FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>This Agreement may be terminated for any reason, at any time, by either the Company, the Agent, upon the giving of
3 days prior written notice to the other party hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Agent may terminate a Terms Agreement to which it is a party, at any time at or prior to the Settlement Date,
(i) if there has been, in such judgment of the Agent, since the time of execution of such Terms Agreement or since the respective
dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, any Material
Adverse Change, or (ii) if there has occurred any material adverse change in the financial markets in the United States or the
international financial markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or any change or
development involving a prospective change in national or international political, financial or economic conditions, in each case
the effect of which is such as to make it, in the judgment of such Agent, impracticable or inadvisable to proceed with the completion
of the offering of Shares contemplated by such Terms Agreement or to enforce contracts for the sale of such Shares, or (iii) if
trading in any securities of the Company has been suspended or materially limited by the Commission or the NYSE American, or (iv)
if trading generally on the NYSE, the NYSE American or Nasdaq has been suspended or materially limited, or minimum or maximum prices
for trading have been fixed, or maximum ranges for prices have been required, by any of said exchanges or by order of the Commission,
FINRA or any other Governmental Entity, or (v) if a material disruption has occurred in commercial banking or securities settlement
or clearance services in the United States or with respect to the systems of Clearstream Banking, soci&eacute;t&eacute; anonyme,
or Euroclear Bank, SA/NV, in Europe, or (vi) if a banking moratorium has been declared by either Federal or New York authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>[Reserved]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>In the event of any termination under this Section 9, no party will have any liability to the other party hereto,
except that (i) the Agent shall be entitled to any commissions earned in accordance with Section 2(b) hereof, (ii) if at the time
of termination (a) the Agent shall own any Shares purchased by it as principal or (b) an offer to purchase any Shares has been
accepted by the Company but the Settlement Date has not occurred, the covenants set forth in Section 3 hereof shall remain in effect
until such Shares are resold or so delivered, as the case may be, and (iii) the covenant set forth in Section 3(h) hereof, the
provisions of Section 4 hereof, the indemnity and contribution agreements set forth in Sections 6 and 7 hereof, and the provisions
of Sections 1, 8, 10, 12, 13, 14, 15 and 16 hereof shall remain in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U><FONT STYLE="font-family: Times New Roman, Times, Serif">. All notices and other communications hereunder
shall be in writing and shall be deemed to have been duly given if mailed or transmitted by any standard form of telecommunication.</FONT></P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Notices to the Agent shall be directed to: BofA Securities, Inc., One Bryant Park, New York, New York 10036, Attention:
ATM Execution (email: dg.atm_execution@bofa.com), with a copy to ECM Legal (Fax: (212) 230-8730).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Notices to the Company shall be directed to it Protalix BioTherapeutics, Inc., 2 Snunit Street, Science Park P.O.B.
455, Carmiel 20100, Israel, Attention: Dror Bashan (email: dror.bashan@protalix.com), with a copy to Mayer Brown LLP, 1221 Avenue
of the Americas, New York, New York 10020, Attention: Anna Pinedo (email: APinedo@mayerbrown.com).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Advisory or Fiduciary Relationship</U><FONT STYLE="font-family: Times New Roman, Times, Serif">. The Company acknowledges
and agrees that (a) each purchase and sale of Shares pursuant to this Agreement, including the determination of the respective
initial public offering prices of Shares, if any, and any related discounts and commissions, is an arm&rsquo;s-length commercial
transaction between the Company, on the one hand, and the Agent, on the other hand, and does not constitute a recommendation,
investment advice, or solicitation of any action by the Underwriters, (b) the Agent has not assumed and will not assume any advisory
or fiduciary responsibility in favor of the Company or any of its subsidiaries or other affiliates with respect to any offering
of Shares or the process leading thereto (irrespective of whether the Agent has advised or is currently advising the Company or
any of its subsidiaries or other affiliates on other matters) or any other obligation to the Company except the obligations expressly
set forth in this Agreement, (c) the Agent, and its affiliates may be engaged in a broad range of transactions that involve interests
that differ from those of the Company, and (d) the Agent has not provided any legal, accounting, financial, regulatory, investment
or tax advice to the Company or any other person or entity with respect to any offering of Shares and the Company has consulted
its own respective legal, accounting, financial, regulatory and tax advisors to the extent it deemed appropriate, and (f) none
of the activities of the Underwriters in connection with the transactions contemplated herein constitutes a recommendation, investment
advice or solicitation of any action by the Underwriters with respect to any entity or natural person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Recognition of the U.S. Special Resolution Regimes<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>In the event that the Agent that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution
Regime, the transfer from the Agent of this Agreement, and any interest and obligation in or under this Agreement, will be effective
to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such
interest and obligation, were governed by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>In the event that the Agent that is a Covered Entity or a BHC Act Affiliate of the Agent becomes subject to a proceeding
under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against the Agent are permitted
to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this
Agreement were governed by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For purposes of this Section 12, a &ldquo;<U>BHC Act Affiliate</U>&rdquo;
has the meaning assigned to the term &ldquo;<U>affiliate</U>&rdquo; in, and shall be interpreted in accordance with, 12 U.S.C.
 &sect; 1841(k). &ldquo;<U>Covered Entity</U>&rdquo; means any of the following: (i) a &ldquo;covered entity&rdquo; as that term
is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 252.82(b)&#894; (ii) a &ldquo;covered bank&rdquo; as that term
is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 47.3(b)&#894; or (iii) a &ldquo;covered FSI&rdquo; as that
term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 382.2(b). &ldquo;<U>Default Right</U>&rdquo; has the meaning
assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81, 47.2 or 382.1, as applicable.
 &ldquo;<U>U.S. Special Resolution Regime</U>&rdquo; means each of (i) the Federal Deposit Insurance Act and the regulations promulgated
thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Parties</U><FONT STYLE="font-family: Times New Roman, Times, Serif">. This Agreement shall each inure to the benefit
of and be binding upon the Agent and the Company and their respective successors. Nothing expressed or mentioned in this Agreement
is intended or shall be construed to give any person, firm or corporation, other than the Agent, its Affiliates and selling agents,
the Company and their respective successors and the controlling persons and officers and directors referred to in Sections 6 and
7 and their heirs and legal representatives, any legal or equitable right, remedy or claim under or in respect of this Agreement
or any provision herein contained. This Agreement and all conditions and provisions hereof are intended to be for the sole and
exclusive benefit of the Agent, its Affiliates and selling agents, the Company and their respective successors, and said controlling
persons and officers and directors and their heirs and legal representatives, and for the benefit of no other person, firm or
corporation. No purchaser of Shares shall be deemed to be a successor by reason merely of such purchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Trial
by Jury</U><FONT STYLE="font-family: Times New Roman, Times, Serif">. Each of the Company (on its behalf and, to the extent permitted
by applicable law, on behalf of its stockholders and affiliates) and the Agent hereby irrevocably waives, to the fullest extent
permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement
or the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 15.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>GOVERNING LAW</U><FONT STYLE="font-family: Times New Roman, Times, Serif">. THIS AGREEMENT AND ANY CLAIM, CONTROVERSY
OR DISPUTE ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF, THE
STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 16.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Consent to Jurisdiction&#894; Waiver of Immunity</U><FONT STYLE="font-family: Times New Roman, Times, Serif">. Each
of the Company and the Agent agrees that any legal suit, action or proceeding arising out of or based upon this Agreement or the
transactions contemplated hereby (&ldquo;<U>Related Proceedings</U>&rdquo;) shall be instituted in (i) the federal courts of the
United States of America located in the City and County of New York, Borough of Manhattan or (ii) the courts of the State of New
York located in the City and County of New York, Borough of Manhattan (collectively, the &ldquo;<U>Specified Courts</U>&rdquo;),
and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement
of a judgment of any Specified Court, as to which such jurisdiction is non-exclusive) of the Specified Courts in any such suit,
action or proceeding. Service of any process, summons, notice or document by mail to such party&rsquo;s address set forth in Section
10 hereof shall be effective service of process upon such party for any suit, action or other proceeding brought in any Specified
Court. Each of the Company and the Agent irrevocably and unconditionally waives any objection to the laying of venue of any suit,
action or other proceeding in the Specified Courts and irrevocably and unconditionally waives and agrees not to plead or claim
in any Specified Court that any such suit, action or other proceeding brought in any Specified Court has been brought in an inconvenient
forum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 17.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>TIME</U><FONT STYLE="font-family: Times New Roman, Times, Serif">. TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT
AS OTHERWISE SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 18.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Counterparts</U><FONT STYLE="font-family: Times New Roman, Times, Serif">. This Agreement may be executed in any number
of counterparts, each of which shall be deemed to be an original, but all such counterparts shall together constitute one and
the same Agreement. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by
the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable
law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and
validly delivered and be valid and effective for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 19.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Effect of Headings</U><FONT STYLE="font-family: Times New Roman, Times, Serif">. The Section headings herein are for
convenience only and shall not affect the construction hereof. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE PAGES FOLLOW]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the foregoing is in accordance with your
understanding of our agreement, please sign and return to the Company a counterpart hereof, whereupon this instrument, along with
all counterparts, will become a binding agreement between the Agent and the Company in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Protalix BioTherapeutics, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Dror Bashan&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eyal Rubin</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Dror Bashan&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Eyal Rubin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;CEO&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SVP, CFO</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>[Signature Page to ATM Equity Offering Sales Agreement] </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Accepted as of the date hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">BofA Securities, Inc.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;/s/&nbsp;Anurag Jindal</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;Anurag Jindal</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;Managing Director </FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As Agent &nbsp; &nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>[Signature Page to ATM Equity Offering Sales Agreement] </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Annex I</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Protalix BioTherapeutics, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">($0.001 par value)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TERMS AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BofA Securities, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">One Bryant Park</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York 10036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Protalix BioTherapeutics, Inc., a Delaware
corporation (the &ldquo;<U>Company</U>&rdquo;), proposes, on the basis of the representations and warranties, and subject to the
terms and conditions, stated herein and in the ATM Equity Offering<SUP>SM</SUP> Sales Agreement, dated September [&#9679;], 2020
(the &ldquo;<U>Sales Agreement</U>&rdquo;), between the Company and BofA Securities, Inc. (the &ldquo;<U>Agent</U>&rdquo;), to
issue and sell to the Agent as principal for resale (the &ldquo;<U>Underwriter</U>&rdquo;), and the Underwriter agrees to purchase
from the Company the shares of Common Stock specified in the Schedule A hereto (the &ldquo;<U>[Initial] Securities</U>&rdquo;)
[, and to grant to the Underwriter the option to purchase the additional shares of Common Stock specified in the Schedule A hereto
(the &ldquo;<U>Option Securities</U>,&rdquo; and together with the Initial Securities, the &ldquo;<U>Securities</U>&rdquo;)]*,[in
each case]* on the terms specified in Schedule A hereto. Capitalized terms but and not defined herein have the respective meanings
ascribed thereto in the Sales Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">[The Company grants an option to the Underwriter
to purchase up to an additional [&#9679;] Option Securities at the price per share set forth in Schedule A hereto, less an amount
per share equal to any dividends or distributions declared by the Company and payable on the Initial Securities but not payable
on the Option Securities. The option hereby granted may be exercised for 30 days after the date hereof and may be exercised in
whole or in part at any time from time to time upon notice by the Underwriter to the Company setting forth the number of Option
Securities as to which the Underwriter is then exercising the option and the time and date of payment and delivery for such Option
Securities. Any such time and date of delivery (a &ldquo;<U>Date of Delivery</U>&rdquo;) shall be determined by the Underwriter,
but shall not be later than seven full business days after the exercise of said option, nor in any event prior to the Settlement
Date (as defined below). If the option is exercised as to all or any portion of the Option Securities, the Underwriter will purchase
that proportion of the total number of Option Securities then being purchased which the number of Initial Securities set forth
in Schedule A hereto opposite the name of such Underwriter bears to the total number of Initial Securities, subject, in each case,
to such adjustments as BofA Securities, Inc. in its sole discretion shall make to eliminate any sales or purchases of fractional
shares. For purposes of clarity, the parties hereto agree that the officers&rsquo; certificate, opinions and letter of counsel
and accountants&rsquo; letter referred to in Section 3(o), (p) and (q), respectively, of the Sales Agreement are required to be
delivered by or on behalf of the Company on the Settlement Date.]*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Payment of the purchase price for, and delivery
of certificates for, the Initial Securities shall be made at the offices of [insert name and address of counsel for the Underwriter],
or at such other place as shall be agreed upon by the Underwriter and the Company, at 9:00 A.M. (New York City time) on the second
(or third, if the pricing occurs after 4:30 P.M. (New York City time) on any given day) business day after the date hereof (unless
postponed in accordance with the provisions of Section 9(c) of the Sales Agreement), or such other time not later than ten business
days after such date as shall be agreed upon by the Underwriter and the Company (such time and date of payment and delivery being
herein called &ldquo;<U>Settlement Date</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, in the event that any or all
of the Option Securities are purchased by the Underwriter, payment of the purchase price for, and delivery of certificates for,
such Option Securities shall be made at the above-mentioned offices, or at such other place as shall be agreed upon by the Underwriter
and the Company, on each Date of Delivery as specified in the notice from the Underwriter to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex I-1</P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Payment shall be made to the Company by
wire transfer of immediately available funds to a bank account designated by the Company against delivery to the Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each of the provisions of the Sales Agreement
not related solely to the Agent, as agent of the Company, is incorporated herein by reference in its entirety, and shall be deemed
to be part of this Terms Agreement to the same extent as if each such provision had been set forth in full herein. Each of the
representations and warranties set forth in the Sales Agreement shall be deemed to have been made at and as of the date of this
Terms Agreement [and] [,] the Applicable Time [and any Date of Delivery].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the foregoing is in accordance with your
understanding of our agreement, please sign and return to the Company a counterpart hereof, whereupon this instrument, along with
all counterparts, will become a binding agreement between the Underwriter and the Company in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">THIS TERMS AGREEMENT AND ANY CLAIM, CONTROVERSY
OR DISPUTE ARISING UNDER OR RELATED TO THIS TERMS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF
THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protalix BioTherapeutics, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accepted as of the date hereof:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BofA Securities, Inc.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">_____________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">* &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Include
only if the Underwriter has an option to purchase additional shares of Common Stock from the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Annex I-2</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>tm2032084d1_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><IMG SRC="tm2032084d1_ex5-1img01.jpg" ALT="">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>
                                                                   <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Mayer Brown LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">1221 Avenue of the Americas<BR>
New York, NY 10020-1001<BR>
United States of America</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">T: +1 212 506 2500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">F: +1 212 262 1910</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">October 1, 2020</TD>
    <TD STYLE="text-align: right; vertical-align: top">mayerbrown.com</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Protalix BioTherapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2 Snunit Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Science Park, POB 455</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Carmiel, Israel</P></TD>
    <TD STYLE="text-align: right; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 4%">Re:</TD>
    <TD STYLE="width: 46%">Protalix BioTherapeutics, Inc.</TD>
    <TD STYLE="text-align: right; vertical-align: top; width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">Ladies and Gentlemen:</TD>
    <TD STYLE="text-align: right; vertical-align: top">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acted as counsel
to Protalix BioTherapeutics, Inc., a Delaware corporation (the &ldquo;Company&rdquo;), in connection with the issuance and sale
by the Company from time to time of shares of its common stock, $0.001 par value (&ldquo;Common Stock&rdquo;), having an aggregate
offering price of up to $30,000,000 (the &ldquo;Shares&rdquo;), pursuant a Registration Statement on Form S-3 (Registration Statement
No. No. 333-230604) (the &ldquo;Registration Statement&rdquo;), filed with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;)
under the Securities Act of 1933, as amended (the &ldquo;Act&rdquo;), the prospectus, dated April 12, 2019 (the &ldquo;Base Prospectus&rdquo;),
and the prospectus supplement, dated October 1, 2020, filed with the Commission pursuant to Rule 424(b) of the Rules and Regulations
of the Act (the &ldquo;Prospectus Supplement&rdquo;). The Base Prospectus and the Prospectus Supplement are collectively referred
to as the &ldquo;Prospectus.&rdquo; The Shares are to be sold by the Company in the manner described in the Registration Statement
and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
this opinion, we have examined copies, certified or otherwise identified to our satisfaction, of: (i) the Certificate of Incorporation
of the Company, dated March 30, 2006, as amended by that Certificate of Amendment, dated August 15, 2016, that Second Certificate
of Amendment, dated January 10, 2019, and that Third Certificate of Amendment, dated December 16, 2019; (ii) the Bylaws of the
Company, dated March 31, 2016; (iii) certain resolutions of the board of directors of the Company, relating to the issuance and
sale of the Shares; (iv) the Registration Statement; and (v) the Prospectus. In addition, we have examined originals or copies,
certified or otherwise identified to our satisfaction, of certain other corporate records, documents, instruments and certificates
of public officials and of the Company, and we have made such inquiries of officers of the Company and public officials and considered
such questions of law as we have deemed necessary for purposes of rendering the opinion set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
this opinion, we have assumed the genuineness of all signatures and the authenticity of all items submitted to us as originals
and the conformity with originals of all items submitted to us as copies. In making our examination of documents executed by parties
other than the Company, we have assumed that each other party has the power and authority to execute and deliver, and to perform
and observe the provisions of, such documents and has duly authorized, executed and delivered such documents, and that such documents
constitute the legal, valid and binding obligations of each such party. We also have assumed the integrity and completeness of
the minute books of the Company presented to us for examination. With respect to certain factual matters, we have relied upon certificates
of officers of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 9pt">Mayer Brown
is a global services provider comprising an association of legal practices that are separate entities including</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 9pt">Mayer Brown
LLP (Illinois, USA), Mayer Brown International LLP (England), Mayer Brown (a Hong Kong partnership)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 9pt">and Tauil
 &amp; Chequer Advogados (a Brazilian partnership).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.75pt; padding-left: 1.45pt; font-size: 10pt">Mayer Brown LLP</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.75pt; padding-left: 1.45pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.75pt; padding-left: 1.45pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; padding-right: 5.75pt; padding-left: 0.3in; font-size: 10pt">October 1, 2020</TD>
    <TD ROWSPAN="2" STYLE="width: 52%; padding-right: 5.75pt; padding-left: 5.75pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-left: 0.3in; font-size: 10pt">Page 2</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon, subject
to and limited by the foregoing, we are of the opinion that the Shares have been duly and validly authorized and, when and if issued
and delivered against payment therefor in the manner contemplated by the Registration Statement and the Prospectus, will be validly
issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not express any
opinion herein concerning any law other than the Delaware General Corporation Law and the federal laws of the United States of
America, as in effect on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hereby consent to
the filing of this opinion letter as Exhibit 5.1 to the Company&rsquo;s Current Report on Form 8-K to be filed with the Commission
on or about October 1, 2020 which will be incorporated by reference in the Registration Statement, and to the reference to us under
the caption &ldquo;Legal Matters&rdquo; in the Prospectus, which is a part of the Registration Statement. In giving such consent,
we do not hereby admit that we are acting within the category of persons whose consent is required under Section 7 of the Act or
the rules or regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">Very truly yours,</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>/s/ Mayer Brown LLP</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Mayer Brown LLP</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>plx-20201001.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +K85w7xRiXgen8uNbXAsWamOabPtzp5xeekhuWh9bXlqTy4irNwCBiurVwEW0e4D -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:plx="http://protalix.com/20201001" elementFormDefault="qualified" targetNamespace="http://protalix.com/20201001">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://protalix.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="plx-20201001_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="plx-20201001_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>plx-20201001_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>plx-20201001_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://protalix.com/role/Cover" xlink:href="plx-20201001.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://protalix.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2032084d1_ex5-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2032084d1_ex5-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  P /,# 2(  A$! Q$!_\0
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IB\M;V]DCCCDN& XWLL4>X@?,5R<DDGH**2DTFD]QN*;NUL%%%%(9_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>tm2032084d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="plx-20201001.xsd" xlink:type="simple"/>
    <context id="From2020-10-01to2020-10-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2020-10-01to2020-10-01">0001006281</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-10-01to2020-10-01">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2020-10-01to2020-10-01">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2020-10-01to2020-10-01">2020-10-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2020-10-01to2020-10-01">Protalix BioTherapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-10-01to2020-10-01">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2020-10-01to2020-10-01">001-33357</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2020-10-01to2020-10-01">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2020-10-01to2020-10-01">2 Snunit Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2020-10-01to2020-10-01">Science Park, POB 455</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2020-10-01to2020-10-01">Carmiel</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="From2020-10-01to2020-10-01">IL</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2020-10-01to2020-10-01">2161401</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2020-10-01to2020-10-01">972-4</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2020-10-01to2020-10-01">988-9488</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2020-10-01to2020-10-01">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2020-10-01to2020-10-01">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2020-10-01to2020-10-01">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2020-10-01to2020-10-01">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2020-10-01to2020-10-01">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2020-10-01to2020-10-01">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2020-10-01to2020-10-01">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-10-01to2020-10-01">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140175277025176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Oct. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct.  01,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Protalix BioTherapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 Snunit Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Science Park, POB 455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carmiel<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">2161401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972-4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">988-9488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M1G#X!-P#<'^EM7WON'-P^6^,\;]02P,$%     @ IXI!48.II0/4 0  ,@8
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M3AI_YHOA/UY_ 5!+ 0(4 Q0    ( *>*05$'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ IXI!4?^V
ML8SM    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ IXI!49E<G",0!@  G"<  !,              ( !RP$
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "GBD%1TF3LRTT$  #2
M$   &               @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ IXI!48.II0/4 0  ,@8   T              ( !CPP
M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "GBD%1EXJ[',     3 @  "P
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52P4&      D "0 ^ @  !A,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2032084d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://protalix.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2032084d1_8k.htm">tm2032084d1_8k.htm</File>
    <File>plx-20201001.xsd</File>
    <File>plx-20201001_lab.xml</File>
    <File>plx-20201001_pre.xml</File>
    <File>tm2032084d1_ex1-1.htm</File>
    <File>tm2032084d1_ex5-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2032084d1_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2032084d1_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20201001_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20201001_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "plx-20201001.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "plx",
   "nsuri": "http://protalix.com/20201001",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2032084d1_8k.htm",
      "contextRef": "From2020-10-01to2020-10-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://protalix.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2032084d1_8k.htm",
      "contextRef": "From2020-10-01to2020-10-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-20-111165-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-20-111165-xbrl.zip
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MG99%;"P,J2ED$_A0MR]>DX+!@S&.[,+T5[&V3;J7PHP(!]&@X:1+JV(T$YT
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MF,:4\D)H=UA$/44L%9.(RP[J.1O3XF06X0^";ZR'+<O.+8E_T%457YP<>0C
M:$,F2,JW(B)OJINZ6^@LE8XV5"K4J(JP\=?%Z,=<@W[7JO]\G!QR<5;=<CBT
MW1"6+66^EG(TDUU5MLV4KNMZ6A!5;3%DUK26(*7Q4LT7\O"QLG!%\=I2""/=
M545;;>F:;B0&4=4V1V9=5QJD1'XK^PM)(Y$\JV%^5VD:,N=5;S'9(J"F"0N$
MMC&8AYK6:U-_3]:)ZG*4$77U2]3.CH8-T+ON##IMF[V#51P$.D,<@OU'/0A5
M45YINF!LB^D]>>:B"Z*FS#4[-I,F,G5-4*18C(& %%I4B+UR\8^MO+8G@NY[
MT6@I7=,!6#4!,61!,6+W!F)2R4,@92DP2Q/5I/6BTI8ZOR0!S+8N3PQ=4+0
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M<;'T45C="&!Z_MH22YTPU:T71T_[3AG+Q']\UG3/66^/)4^8],:$TCRTK/J
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MZYI[C-\X(8ICHT3Z]B4TAII@770.=-VX _X%P-49_\N_Y-8=^1]02P,$%
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M*4M,FTCY+76;F)WWH</M,<3OV9JK ;3J4.E1 \185ER@@4C[V=S'-H^Y,\,
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MR:1I\!VZIFLSYBZ[(*YIX1/"6,*UK]KM3(LU\XI8Y7BQNM]^*A>N>O?PL+K
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M+3&1(RP*XC\$:7+4]&C+8PC(<DO@3G&8HEDV2:N**<3J%>D L@I)7L\T0&N
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MLJCD$]TDU$VYDK8,4@NJ,46W/2DCXHE<-TQ _WF2.(*>'*&(Q*:?$PFCM3K
M7\/+K/W#4N+P:.^$86P<@ CF2.,8%==LDN%#V[<S,S)$;BR2H0=+E$XK?S[E
M/+T*?M/>(L&9E$$S=S)_OB4#YM]@L6"'$=CP./@C)ZF\G.7<7W!0ZUDN?4/<
M&W 7YDWN\FW-*8C@)M/:(FF<(LU$? 93#3<?/*KT\NQ#ZL1'#(?[(Q9?P>4_
M[F4CMP+*FH4V'YB_#GS:L_QDM\(>;X7H6:C6,G,.!9^:3Q"THAO,L>-,=D/H
M-L;6X%9+EI&!W+DT[AH$0LZ&W%%L"RU)6U1U-6H2J%%&,',\T&VB6$TS)RR4
M<<- SR1Y15GLF"$>6FXT=CYM"><0%K0I'/<&SRV?LWL/0/>[NCDP< H9@BEB
M(X^*DR 8$?4,'N81G'[ \!@>,SZEA;U@[\?1R.C]QK,\-=F*8@C$FX0M]V"A
M0(ZE%3>_J='/PFBW3^9KB $'1^%UBKVZ TP5F<)QAB=!HK&=SZ;L@N,*-U=V
MU8P"^)V?A><!4R6<HN!6F4W+I/$Q7C^XR%)1@C^C &W'KM)B7(U;&Q'(]:BH
M%,9.!K9I=45$*C.51Q'0KY%&G&H?B*[%Y!1 <C5RM"FN+>GB+*T6.:IAA ?D
MU(1U6?+^Z[B@DG=WXMH003L],NY.="P'1EN%0E)N7Z2JAX8#IK/CLU,;UB)_
M>B8"76[!3+:VZ2,%L$7"H6J039.2E5F?9HOY=EN354BX&01$G0;!B,"LES=1
M.7' HXTWQ# I#@O!VF-AU=P;+XQRVRRCO?5+@QS@#32I"6G6F*>!V6P5)"<1
M<3>+F.>:!">;6T5([7I;C+YKK<GFLARQ'=,&!5-82(S=E*F/5)-QFX8I:Y;X
M%/1^_ZT(:^R$GKQ_Q]"3][^A)V]B,.;+DW5&PS#4&YW%<5] AALSMB(N5XRB
M&%O34]4&]N_K@&[MU)3U:'+"_<)&BK".@]XCBI,Q*=3P1CP5J1PSQ$H$TVJP
M$9X@/6(AY&OITV.D\\%P\$)<E3,?;):*E<JG N0/V8>\;BSPWO>^R4G#.>O!
M&7(NU3V/@V6HEK3]%\_64E*$BJR$329"KE:8@]WU7&A) Q'P M\^'*R+IEIG
MQH8@8\HA,A$Y0DX=+64IO0#;%SA;0J@]&]^SB4876MQDCY)OYC!X LNAK'"#
MK:X76<J&$U>LTART(BF;U[OK=G?GJ7O[<-![?SQ_'YG3B^0CYQ0L/KS"SYD?
M>73RDOC<)<[8/CEUL)VP;I?V=)LG&G/P>;O^QB4/J\35/V_=F1@DN,K*<2Q@
MV]3O0-<J]JSX"Y>(K!$3CIOS;7'G*PG1LE4KV;YR.&C%"L3I0] -@M)-IE$A
M6MX%(B=,G"4CRL:$R?!AA_XX)2(7A5,W.+O2^D<]:[/2I;7GPSFCBX-)(X<Q
MM0HJ75)U%\XF10/0RY 6/A1Z8FXC7= *%=X8>92*O+;0?GK?% 1O5NNR<[N5
MON_$"-(3@4M%K'-Q@K<]XA+JUV$>=HPH#P>S#/%8\/4^PAD)(*#FY?^VZ)"L
MPYM3Z[=%69S SH8#?I(+@Q9]?[K1NWQ$#8T($C1.A)J/:?G&$3"K+0RH,BKQ
MQ(DDU]D40VA?QAZ6AHZSSAVH:;2\";8O<81^(*)V;<[>P"<YEG [?+2ODJT3
M;./G[M"_XVC[L:XTQV.\E]UG'6^5ESGU^FPXQ$5BQVXQ,L.N/0?4KP+)+FQ9
M+QL2>DDW=^ C09+6LQ'@'9)V*/8BD>Z11U^%6,R(_G-:SF"RA'Z$\Z7Q.$D
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M*+6Y\:C5/\8\D"T!'Q3=A Z*T"<@P LI_ETZ.C2.K*.'*0:T>[)6W#2;C=3
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MV$T&1/VX<VAV.LW#AOS3W8Z !_C_1O.X6R[586L!E[8_MCIP?[.K]H_:L.^
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M3)4Y!J:U%Q"=ET:B];B,&2C5T!E+ ZT%JN%F$**O$MH%0\Q%B"L&6U$(AND
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M)U(Y>4GJ;:G'4EC(70 /D![9-(@B$Z4T"8;O7 >A+9HW]&5Y(/@)#NM,3Q"
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MK%G7OU9C[BM#]!]K_K<,)#1=IK_QN S<X1B/B:G@Y)=ZG;V6(O /V"4?BT,
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M9SL+7Z7R;?JGBO2_+.B?,?X+4$L! A0#%     @ IXI!45,M+P4[ P  C P
M !               ( !     '!L>"TR,#(P,3 P,2YX<V102P$"% ,4
M" "GBD%1>$W+X/T*  #?AP  %               @ %I P  <&QX+3(P,C Q
M,# Q7VQA8BYX;6Q02P$"% ,4    " "GBD%1QR "G54'   S60  %
M        @ &8#@  <&QX+3(P,C Q,# Q7W!R92YX;6Q02P$"% ,4    " "G
MBD%1#.\&'ZX5  !K?   $@              @ $?%@  =&TR,#,R,#@T9#%?
M.&LN:'1M4$L! A0#%     @ IXI!44 #Y4H&F0  PED# !4
M ( !_2L  '1M,C S,C X-&0Q7V5X,2TQ+FAT;5!+ 0(4 Q0    ( *>*05$*
M_4B,(PL  ),Q   5              "  3;%  !T;3(P,S(P.#1D,5]E>#4M
;,2YH=&U02P4&      8 !@"( 0  C-

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
